



20 July 2022

Dear Valued Shareholders,

RE: DRAFT MINUTES OF THE 21ST ANNUAL GENERAL MEETING OF DUOPHARMA BIOTECH BERHAD HELD ON TUESDAY, 21 JUNE 2022

Duopharma Biotech Berhad (the "Company") is pleased to inform that the draft Minutes of the 21st Annual General Meeting of the Company held on Tuesday, 21 June 2022 ("AGM") have been published on our website at the Investor Relations section. Please note that the draft Minutes is subject to amendments and subject to approval by the Board of Directors.

The Minutes have incorporated the Questions received from Shareholders or the Proxies/Corporate Representatives during the AGM and the answers thereto.

Thank you.

Yours faithfully
for and on behalf of

DUOPHARMA BIOTECH BERHAD

LEONARD ARIFF BIN ABDUL SHATAR
Group Managing Director

DUOPHARMA BIOTECH BERHAD

Registration No: 200001021664 (524271-W)

Suite 18.06, Level 18, CIMB HUB, No. 26, Jalan Sultan Ismail, 50250 Kuala Lumpur, Malaysia.

General line +603 2162 0218 Fax +603 2161 0507 www.duopharmabiotech.com



DUOPHARMA BIOTECH BERHAD
Registration No. 200001021664 (524271-W)
Incorporated in Malaysia

MINUTES OF THE TWENTY-FIRST (21ST) ANNUAL GENERAL MEETING HELD ENTIRELY THROUGH LIVE STREAMING FROM THE BROADCAST VENUE AT THE MEETING ROOMS 403 & 404, LEVEL 4, KUALA LUMPUR CONVENTION CENTRE, KUALA LUMPUR CITY CENTRE, 50088 KUALA LUMPUR, MALAYSIA (THE “BROADCAST VENUE”) AND VIA THE TIIH ONLINE WEBSITE AT <https://tiih.online> ON TUESDAY, 21 JUNE 2022 AT 9.00 A.M.

PRESENT AT THE

BROADCAST VENUE

- : YBhg Tan Sri Datin Paduka Siti Sa’diah bin Sh Bakir
- Chairman (Also a Proxy) (the “Chairman”)
- Encik Leonard Ariff bin Abdul Shatar
- Group Managing Director
- YBhg Dato’ Mohamad Kamarudin bin Hassan
- Senior Independent Non-Executive Director
- Encik Razalee bin Amin
- Independent Non-Executive Director
- YBhg Dato’ Eisah binti A. Rahman
- Independent Non-Executive Director
- YBhg Datuk Nik Moustpha bin Hj Nik Hassan
- Independent Non-Executive Director
- YBhg Datuk Mohd Radzif bin Mohd Yunus
- Non-Independent Non-Executive Director
- YBhg Dato’ Dr. Zaki bin Yunus
- Independent Non-Executive Director
- Puan Amizar binti Mizuar
- Non-Independent Non-Executive Director
- Encik Ibrahim Hussin Salleh
- Company Secretary
- Mr. Chek Wu Kong
- Chief Financial Officer
- Encik Ameenuddin Bin Khali Kasman
- Partner, KPMG PLT (Auditor)
- Mr Krishman Varges a/l PV John
- KPMG Management & Risk Consulting Sdn. Bhd.
(Independent moderator for questions & answers session)
- Ms. Cheryl Leong
- KPMG Management & Risk Consulting Sdn. Bhd.
(independent moderator for questions & answers session)

Ms. Thirshalar Padmanabhan

- KPMG Management & Risk Consulting Sdn. Bhd.
(independent moderator for questions & answers session)

Ms. Sharumathi M Kavi Rajan

- KPMG Management & Risk Consulting Sdn. Bhd.
(independent moderator for questions & answers session)

**DIRECTORS' PRESENT VIA
WEBEX FACILITY:**

Puan Zaiton binti Jamaluddin

- Independent Non-Executive Director

**PRESENT OUTSIDE THE
BROADCAST VENUE**

: Encik Wan Amir-Jeffery bin Wan Abdul Majid

- Chief Operating Officer/ Chief Commercial Officer

Encik Shamsul Idham bin A.lahad

- Chief Executive Officer, Duopharma Consumer Healthcare Sdn. Bhd.

Mr. Rama Sockalingam A/L Nagappan

- Head, Group Internal Audit and Integrity
(Observer)

Ms Priya Darshini Asokan

- General Manager, Strategy and Business Development

Mr Vinc Choong Jia Liang

- Manager, Corporate Finance

Mr Kelvin Gan Rion

- Executive, Finance Department

Puan Suzana binti Abdul Rahim

- Tricor Investor & Issuing House Services Sdn Bhd
(Poll Administrator)

Ms. Samantha Goh

- Tricor Investor & Issuing House Services Sdn Bhd
(Poll Administrator)

Cik Nur Qaisara Naaila @ Nella Nyoyew

- Tricor Investor & Issuing House Services Sdn Bhd (Poll Administrator)

Ms. Kar Hue Leow

- Scrutineer Solutions Sdn. Bhd. (Scrutineer)

**PRESENT OUTSIDE THE
BROADCAST VENUE/
PRESENT BY WAY OF
TIIH ONLINE**

- : Ms. Ng Su Yee
- Chief Technical Officer
Mr. Krisnakumara-Reddi a/l Kesava-Reddi
- Chief Manufacturing Officer

[The above attendees were as listed in Annexure I of the Minutes of the 21st AGM of Duopharma Biotech Berhad (the “AGM” or the “Meeting”).]

[The attendance of Members/Corporate Representatives/Proxies was as per the Summary of Attendance List by way of Remote Participation and Voting (“RPV”) at TIIH Online in Annexure II of the Minutes of the Meeting].

QUORUM

According to Article 69 of the Company’s Constitution, the quorum for the meeting shall be two (2) members present in person. A ‘member’ includes a proxy and a corporate representative, according to Articles 69, 82 and 83(3)(a) and 90 of the Company’s Constitution, respectively.

Based on the registration data given by the Company’s Share Registrar as of 9.00 a.m. on 21 June 2022, there were 108 shareholders that had registered through the Remote Participation and Voting (“RPV”) facility for attendance at the Meeting, representing 495,919,448 ordinary shares which constituted 52.07% of the total issued shares of the Company. In addition, the Company had received 143 valid proxies totalling 659,414,476 shares representing 69.25% of the Company’s issued and paid-up share capital.

As the number of members present was sufficient, the Secretary confirmed that a quorum was present.

NOTICE OF MEETING

The notice convening the Meeting dated 28 April 2022 was tabled and taken as read.

CHAIRMAN’S OPENING REMARKS

The Chairman highlighted that with Malaysia currently in the ‘Transition to Endemic’ phase of Covid-19, the situation still warranted everyone to be cautious as the Covid-19 virus was still in the midst.

In view of this, the Board of Directors of the Company decided that the 21st AGM be conducted as a virtual meeting in line with the latest guidance for conducting a fully virtual meeting as issued by the Securities Commission Malaysia (the “SC Guidance”). Pursuant to the SC Guidance and Section 327 Subsection (2) of the Companies Act, 2016, the Chairman shall be present at the main venue of the AGM (i.e., the broadcast venue) to chair the AGM and shareholders would not be physically present at the broadcast venue on the day of the AGM.

Tan Sri Chairman introduced all members of the Board and Senior Management who were present at the Broadcast Venue. Puan Zaiton binti Jamaluddin, an Independent Non-Executive Director of the Company was slightly unwell and unable to join the AGM from the Broadcast Venue. Nevertheless, she was virtually present and was introduced by Tan Sri Chairman together with the other members of the Senior Management that were present via video conferencing.

Before the Chairman proceeded with the business of the Meeting, the performance of Duopharma Biotech Group for the year 2021 was highlighted as follows:-

- (i) the Company performed well with an increase in revenue by 12.2% year-on-year to RM639.2 million while achieving an increase in profit after tax (“PAT”) by 12.1% to RM65.7 million;
- (ii) the total dividend paid for the financial year ended 31 December 2021 amounted to RM20.49 million or 31.19% of the Company's PAT;
- (iii) the Company maintained a very high On Time In Full performance of 98.8% in 2021 as compared to 98.4% in 2020;
- (iv) the Company continued to expand its Consumer Healthcare and prescription products in order to provide better solutions for healthier lives. Firm in the belief that beauty comes from good health, the Company launched supplements that enhance beauty. The Company also continued to introduce more biotherapies to treat cancer, diabetes and heart diseases while accelerating the development of digital therapies;
- (v) in efforts to enhance inclusivity in healthcare, the Company was committed to the development of halal certified treatments, ensuring everyone around the world had access to therapies and medication for their well-being. The Company embraced the concept of *halalan toyibban* whereby almost all of the drugs manufactured at the Company's plants had an added layer of assurance beyond compliance with Good Manufacturing Practice (GMP) by carrying the halal signature of being safe, effective and of high quality and hygienic; and
- (vi) as global issues such as climate change, access to healthcare and corporate integrity become more pertinent, the Company was redoubling efforts to ensure it had the right systems, processes and framework to support its ESG agenda. This can be clearly seen whereby the Company had incorporated the 2021 Annual Report theme as “Driving ESG into the heart of our business” demonstrating its commitment to ESG. In this regard, the Company was working with sustainability experts such as the United Nations Global Compact Network Malaysia and Brunei (UNGCMYB) to reduce carbon emissions as the Company contributes to the transition to a low-carbon economy. The Company's ambition was to become carbon neutral by 2030 and achieve net zero emissions by 2050.

The Chairman expressed her appreciation and gratitude as follows: -

- (a) the Company's shareholders, as well as customers, business partners and suppliers, for their continued support and trust in the Company
- (b) the Government and related agencies, particularly the Ministry of Health, the Ministry of Science Technology and Innovation, and the Ministry of Finance for their unrelenting commitment demonstrated in battling the Covid-19 pandemic, and for always keeping the nation's well-being at heart;
- (c) the country's frontliners, who continued to work so hard and selflessly to keep the nation safe;
- (d) the Board Members for their time and wise counsel;
- (e) the Group Managing Director, Encik Leonard Ariff, for continuing to inspire the Management and employees to do and achieve more; and
- (f) to all employees for sharing in the Company's vision, mission and values, and their invaluable efforts to serve the Company and the nation.

GENERAL INSTRUCTIONS ON MEETING PROCEDURES

The Company Secretary briefed the shareholders, corporate representatives and proxies present virtually at the Meeting on their right to ask questions and vote on the resolutions on the agenda of the Meeting.

He informed that pursuant to Paragraph 8.29A(1) of the Bursa Malaysia Listing Requirements, all resolutions in the Notice of Annual General Meeting which were put to vote shall be decided on a poll and that every member present in person or by proxy shall have one (1) vote for each share he/ she holds.

The Company had appointed Tricor Investor & Issuing House Services Sdn Bhd ("Tricor") as the Poll Administrator to conduct the poll for the Meeting and appointed Scrutineer Solutions Sdn.Bhd. to verify the poll results. To allay concerns by shareholders that companies may selectively avail and respond to questions in a virtual general meeting environment, the Company had also appointed KPMG Risk & Management Consulting Sdn Bhd ("KPMG") as an external party to lend objectivity and transparency by streaming the questions raised.

The Board members and the Senior Management of the Company were present to answer any questions from members on the matters set out in the agenda for the Company's 21st AGM.

The shareholders were to use the TIH Online Query Box, as the primary mode of communication, to raise question(s) during the virtual AGM and the Company would endeavour to respond to all questions posed during the virtual AGM. The Company would respond to all relevant unanswered questions via the website within one (1) month from the virtual AGM date.

A short video presentation on the demonstration of the online e-voting process was broadcasted by Tricor, the Company's Poll Administrator. The voting session commenced from the start of the Meeting at 9.00 a.m.

Before the meeting proceeded to the agenda proper, the Chairman informed the shareholders who had appointed her as their proxy that she will vote in accordance with their instructions. The Chairman then briefed the shareholders, corporate representatives and proxies present virtually at the Meeting on the conduct of each agenda item for the Meeting to adapt in the most practicable way for the virtual meeting.

For the purpose of the meeting, both Ms. Ng Su Yee, the Chief Technical Officer, and Mr. Krisnakumara-Reddi A/L Kesava-Reddi, the Chief Manufacturing Officer, who were also the shareholders of the Company and were virtually present at the Meeting, had offered themselves to be the proposer and seconder for all the motions and proposed resolutions in the agenda of the Meeting.

With respect to the submission of questions for this 21st AGM, the Company had allowed shareholders to submit their questions online prior to the meeting and the Company had received a number of questions. The Chairman further informed that the Company received a letter from Minority Shareholders Watch Group (MSWG) on 13th June 2021. In the interest of minority shareholders and other stakeholders of the Company, MSWG, in its letter, has raised a few points in relation to this AGM.

The shareholders could still continue to submit their questions online using the TIHH Online Query Box facility during the Meeting. As questions from shareholders may not be in the sequence of the Agenda and one shareholder may wish to submit questions for several Agenda items, the Group Managing Director and the Management team would be invited, after the Chairman had gone through the proposed resolutions in the Agenda, to assist the Board in responding to the questions received prior to as well as during the 21st AGM.

The Chairman further informed the Meeting that none of the directors of Duopharma Biotech were shareholders of the Company except Datuk Mohd Radzif Bin Mohd Yunus, who held 25,293 shares of Duopharma Biotech. As such, Datuk Radzif had abstained from voting on the proposed resolutions 5 and 6 concerning the remuneration for Non-Executive Directors.

AGENDA NO. 1:

To receive the Audited Financial Statements for the financial year ended 31 December 2021 and the Reports of the Directors and Auditors thereon.

- (a) The Chairman tabled the Audited Financial Statements (“AFS”) for the financial year ended 31 December 2021 (“FY2021”) and the Reports of the Directors and Auditors as set out on pages 110 to 187 of the Company’s Annual Report (“AR”) 2021.
- (b) The Chairman declared that the AFS for FY2021 and the Reports of the Directors and Auditors laid in the AGM in accordance with Section 340(1)(a) of the Companies Act 2016 were duly received. As Agenda item No. 1 was meant for discussion only and did not require the approval of shareholders, it would not be put forward for voting.
- (c) The Chairman invited Encik Leonard Ariff, the Group Managing Director (the “GMD”), to brief on the performance of the Company for the year 2021.

- (d) The GMD presented the performance of the Company for the year 2021 including the Company's plans moving forward, as follows:-

(1) Corporate Structure

The corporate structure has remained flat in terms of the equity structure of its subsidiaries. Duopharma Biotech held interests in a number of overseas companies of which interest comes with strategic purposes. The details were highlighted later in the GMD's presentation.

(2) Structure of the Board of Directors

There were five (5) Board Committees consisting of the Nomination and Remuneration Committee, Audit and Integrity Committee, Risk Management and Sustainability Committee, Halal Committee and Medical Advisory Committee. These Board Committees provide guidance both to the Board of Directors and Management in addressing day to day issues.

(3) Structure of the Group Management Committee

The Group Management Committee ("GMC") was led by the GMD and its members comprised the Chief Operating Officer/ Chief Commercial Officer, the Chief Financial Officer, the Chief Technical Officer, the Chief Manufacturing Officer, the Chief Legal Officer and Group Company Secretary, and the Chief Executive Officer of Duopharma Consumer Healthcare Sdn. Bhd.

Separate from the GMC, other key management included the Head of Group Risk Management and the Group Internal Auditor who reported directly to the Chairman of the Risk Management and Sustainability Committee and the Chairman of the Audit and Integrity Committee respectively and on a dotted line basis to the GMD. Both the Head of Group Risk Management and the Group Internal Auditor stood separate from the GMC in order to provide independent oversight on the Group's risk management and internal control systems.

(4) Financial Highlights

The year 2021 was a good year for the Company as it achieved the highest Profit Before Tax ("PAT") of RM83.0 million with an increase in the Earning Per Share from 6.31 sen to 7.08 sen. Although the Company operated during the pandemic period in 2021, and despite the uncertainty of the opening of the economy and 2021 being considered challenging, the Company had carefully managed its cash flow and the Company managed to pull through with stellar performance for the year 2021.

With respect to the Company's performance, the revenue increased from RM570 million in 2020 to RM693 million in 2021. The Group's Profit Before Tax ("PBT") and PAT had been steadily increasing year-on-year. The revenue in 2021 was largely driven by the CHC business and also by double-digit growth of the Ethical Classic and Ethical Specialty businesses. However, lower revenue was contributed by the Company's export section due to the issue in logistics for COVILO, closure of borders and the slow recovery of the supply chain arising from lockdowns. Higher sales throughout the current year ended 31 December 2021 had led to enhanced PBT as compared to 2020.

As for the balance sheet, the Group's Current Assets, Non-Current Assets, Equity and Liability recorded an upward trend from 2017 to 2021. The gearing ratio was increased over the last few years as it was utilized for the construction of the Company's facilities under the Manufacturing Optimisation Plan. Some major work that was performed in 2021 albeit the pandemic was the 3 months shutdown of the Company's facility in Bangi which has led to a buildup of stocks over the course of the year. The Return on Equity has recovered at a double digit, i.e., 10.5%, as compared to 9.1% in 2020.

Concerning the construction of K3 and K5 facilities which was on-going, the Company was bullish on targeting to obtain a Certificate of Practical Completion for K3 within the financial year 2022.

The CAPEX within the Group has largely been financed by a term loan that was granted by AmBank of which the Company has drawn down RM178 million as at 31 December 2021.

During the financial year 2021, the Company further invested USD500k into a wellness company known as Naluri Hidup Sdn. Bhd..

The Company declared an interim dividend of 0.5 sen per share that was paid on 15 September 2021 and a second interim dividend of 1.8 sen per share that was paid on 13 May 2022. The total dividend paid for FY2021 was 2.3 sen per share or 31% of the PAT. On an absolute dollar basis, the total dividend was slightly lower as compared to the previous year as part of the Group's de-gearing strategy as well as to conserve cash as working capital and to fund existing business expansion. A lot of the loans that were taken due to the capital expansion would be due for repayment in 2023. The Company would manage the repayment of the loans and de-gearing.

(5) Financial Highlights (Segmental Sales)

In terms of the source of revenue of the Group, the GMD highlighted that the public sector exposure over the course of the last three years has reduced from 49% in 2019 to 47% in 2020 and 45% in 2021. Correspondingly, the local or private sector sales have increased from 43% in 2019 to 45% in 2020 and 49% in 2021. The export segment has softened from 8% in 2019 and 2020, to 7% in 2021. As for the Export segment, Singapore tended to be the largest export market for the Company, followed by the Philippines, and the Middle East.

(6) Key Highlights

The data presented on the Key Highlights was for the Shareholders' information on the Group's achievements over the course of the last few years, including 2021.

It was highlighted that Duopharma Biotech was the first domestic company to:-

- (1) Establish a small volume injectables (SVI) plant;
- (2) Establish a dental cartridge facility for the production of Denken;
- (3) Establish a soft gel plant in Malaysia using the Pharmagel technology from Italy;
- (4) Establish a dedicated sterile ocular facility;
- (5) Set up an internal pharmacovigilance capability among generics companies in Malaysia;
- (6) Receive NPRA approval for inert vaccine/ biotech fill and finish (F&F) facility;
- (7) Register First Biosimilar Protein Therapeutics i.e., Erythropoietin ("EPO");
- (8) Register First Biosimilar Antibody i.e., Trastuzumab;
- (9) Establish a state-of-the-art intermediate bulk container (IBC) plant in Bangi ;
- (10) Conduct a joint Phase 3 clinical study for a biosimilar in Malaysia and Korea with PanGen Biotech Inc.;
- (11) Obtain approval for registration of the first locally developed biosimilar product, i.e., Erythropoietin;
- (12) Receive Halal certification for Consumer Healthcare products;
- (13) Receive Halal certification for ethical products based on MS2424 which was the World's first Halal Pharmaceutical Standard;
- (14) Establish an effervescent technology facility in Bangi; and
- (15) Set up and operate a Highly Potent Active Pharmaceutical Ingredient ("HAPI") Facility.

The Company was the first in Malaysia to commercially produce (domestically manufactured) a cancer drug i.e., Letrozole, used in the treatment of breast cancer with a trading name of Lebreta, in both the public and private sectors in Malaysia. The Company would be launching a new product from the same facility as well.

Some of the key highlights in terms of the Group's accreditations were as follows:

- (1) GMP – Manufacturing License by the National Pharmaceuticals Regulatory Authority (NPRA) Malaysia;
- (2) ISO 9001:2015 Quality Management System;
- (3) ISO 13485:2016 Quality Management System for Medical Devices;
- (4) MS ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories;
- (5) GDPMD – Good Manufacturing Practice for Medical Device;
- (6) GMP by TGA (Australia); and
- (7) ISO37001 (Anti-Bribery Management Systems) certification for Duopharma Biotech Group including the Philippines and Singapore subsidiaries.

Moving forward, the Company would be looking towards obtaining EU Certifications for all of the Company's facilities on a phased approach, starting with the HAPI facility followed by Bangi and Klang facilities. This would facilitate the ability to export products more readily from the Group's entire operations.

The Company was the first pharmaceutical company to obtain the Malaysian Halal certification from Jabatan Kemajuan Islam Malaysia (JAKIM) in 1999. In 1999, there was no separate Halal Certification for pharmaceutical and Consumer Healthcare ("CHC") products where pharmaceutical and CHC products were registered under the food category. The Company believed in the journey in Halal, and developed products that benefitted the whole population of Malaysia and export markets. Halal products certified by JAKIM benefitted everyone as they were safe for consumption, used quality ingredients/materials in their production, were efficacious, and were hygienically processed. Further, this certification was over and above the GMP certification. The Company also obtained the Indonesian Halal certification from Majelis Ulama Indonesia in 2014 and Halal Certification from Korea Muslim Federation for Duopharma Biotech's Renal Medicine i.e., ERYSA.

The Company won the Halal Healthcare Excellence 2022 at the World Halal Excellence Award organised by the Halal Development Corporation Berhad for its initiative in manufacturing quality products and services and propelling the healthcare industry to be a renowned global halal pharmaceutical provider.

Separately, the Company also won the following awards over the course of the year:-

- (i) Malaysia Pharmaceutical Company of the Year for 2013, 2016, 2018 and 2019 by Frost Sullivan Malaysia;
- (ii) Halal Pharmaceutical Company of the Year for 2017, 2018, and 2019;
- (iii) Best Companies to Work for in Asia for 2016, 2017, 2018, 2019, 2020 and 2021 by HR Asia;
- (iv) Most Attractive Graduate Employers to Work for in 2021 by the Graduates' Choice Award;
- (v) 5 Petals Gold Ethics Award 2020 by the Business Ethics Institute of Malaysia;
- (vi) Winner for Risk Champion and Runner Up for Risk Innovation Category at the ASEAN Risk Awards 2021 by the Enterprise Risk Management Academy;
- (vii) Silver award at the Australasian Reporting Awards for the Company's Annual Report; and
- (viii) Silver Excellence Award at National Annual Corporate Report Awards (NACRA) 2020 in the category of companies with a market capitalisation of less than RM2 billion.

During the year, the Company again qualified to be listed under the FTSE4GOOD Index Series created by FTSE Russell which was designed to measure the performance of companies demonstrating strong Environmental, Social and Governance ("ESG") practices and future aspirations of companies. The Company had been the constituent for FTSE4GOOD for a few years now and had recently undergone FTSE4GOOD review for the 3rd time. The Company hoped to remain as one of the constituents of the FTSE4GOOD index series.

Separately, Duopharma Biotech was highlighted in 2019 by the MSWG-ASEAN Corporate Governance Awards as the runner-up in the Corporate Disclosure Category for companies with a market capitalisation between RM300 million and RM1 billion.

Duopharma Biotech was the; (i) Overall Winner for the outstanding and comprehensive efforts in corporate sustainability in the Large Company category for 2021, (ii) Winner for Business Ethics and Responsibility, Stakeholder Management, UN Sustainable Development Goals in the Large Company category for 2021; and (iii) Significant Achievement in Water Management, Waste Productivity and Materiality in the Large Company category for 2021 by the Sustainable Business Award. The Company was also the Winner of Sustainable Development Goals (Ambition Benchmark 10 Award: Zero incidences of bribery due to the Group's strong sustainability governance and anti-corruption) for 2021 by the UN Global Compact.

Duopharma Biotech would not have achieved all the successes without continuous collaboration with its various Key Partners, i.e., Natco, Biocon, Embecta, SCM Lifescience Co. Ltd. and PanGen Biotech Inc. Some collaboration started as far back as 2010 where the Company had a relationship with a company called Natco which assisted the Company with the construction of the HAPI facility and continued to assist the Company with the availability of dossiers. The Company worked very closely with Biocon from India who has a manufacturing facility in Johor. The Company represents Biocon in the Malaysian market.

The Company had recently announced a contract with the Government of Malaysia to continue supplying insulin sourced from Biocon. Further, is the Company also represented Embecta, which was involved in the diabetes sector as well. Duopharma Biotech had invested in SCM Lifescience Co. Ltd., a Korean company involved in stem cell technology. The Company had also invested in PanGen Biotech Inc which has assisted the Company on the registration for EPO in Malaysia and provided the Company technology that allowed fill and finish of Erysaa. Duopharma Biotech is proud to be associated with these Key Partners that supported the Company's commitment and would continue to search for new partners that would assist the Company's growth into the future.

Some of the key highlights of the Company's vision by the year 2025, were presented as follows:-

- (i) Aspiration to hit a revenue of RM1 billion on a constant basis as opposed to having a one-off project;
- (ii) To ensure all of the Company's practices followed the Good Distribution Practice;
- (iii) Similarly, all storage complies with the Good Storage Practice as well in addition to the Good Manufacturing Practice;
- (iv) Halal represents a key pillar of Duopharma Biotech where all products developed and eventually marketed to be halal certified;

- (v) Duopharma Biotech, was a great believer in innovation and had invested quite a fair amount in the Company's Research and Development ("R&D") in addition to bringing new innovation from the Key Partners;
- (vi) Duopharma Biotech would continue to look into innovative areas;
- (vii) To have a strong position in ASEAN, before growing beyond ASEAN;
- (viii) As Malaysia was already a member of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme ("PIC/S") the Company had obtained the Good Manufacturing Practice ("GMP") certification from the local authority and the Australian Therapeutic Goods Administration ("TGA") certification. The Company intends to increase its compliance to ensure all manufacturing facilities would eventually comply with the European Medical Agency ("EMA") requirements as well.
- (ix) Once the Company obtained EMA compliance, Duopharma Biotech would be able to be a supplier for selected products on a regional basis;
- (x) In terms of the type of products moving forward and since the generic sector is becoming competitive, the Company would continue to focus on biologics and niche therapeutics products that were not commonly manufactured within the region. With EMA certified facilities, the Company hoped to be able to increase the level of export as a percentage of the total revenue portfolio; and
- (xi) Ultimately, Duopharma Biotech aimed to be the top 5 generic pharmaceuticals company in ASEAN.

(7) Investment in SCM Lifescience Co. Ltd. ("SCM Lifescience")

Since Duopharma Biotech is not a private equity company, all investments made by the Company in third-party companies were for strategic purposes. In the case of SCM Lifescience, investment was primarily due to their work in stem cells. Malaysia previously planned to introduce regulations on stem cells, and on this view, the Company acquired a 5.8% stake in SCM Lifescience worth approximately RM20.24 million via a Share Subscription Agreement dated 25 October 2018 to have access to technology as well as manufacturing capability. Post-acquisition of Duopharma Biotech shares in SCM Lifescience, SCM Lifescience subsequently acquired a 51% equity in a US company called Colmmune – an entity with an immuno-oncology global cell therapy cGMP facility in the United States. The Company now had access not only to the technology but to theoretical manufacturing capability as well.

Soon after SCM Lifescience was listed on KOSDAQ on 17 June 2020, the Company sold approximately 50% of its equity or a total of 218,688 shares and retained another 50% of the equity for a strategic purpose. The Company was able to recoup its overall investment in SCM Lifescience.

(8) Investment in Naluri Hidup Sdn. Bhd.

In the case of Naluri Hidup Sdn. Bhd. ("Naluri"), the Company understood that the landscape for healthcare was changing rapidly and digital therapeutic and digital healthcare offerings were increasing and the Company had to look at the possibility of how this sector would evolve and participate in the journey. Naluri was a company that approached Duopharma Biotech. Naluri developed a proprietary application platform called "Naluri App" that focuses on wellness with a high emphasis on mental healthcare and combines behavioural science, data science, as well as digital design, to offer a holistic health management programme for users. The programme was targeted on a Business-to-Business basis, and the Company took an early stage of investment on a Simple Agreement for Future Equity (SAFE) basis. Subsequently, the Company invested a further USD 500,000 in Naluri's Series A funding.

In return for this investment, the Company obtained access to utilising Naluri's platform and development of applications to support the sale of our pre-existing products which were currently a work in progress.

(9) Investment in AZTherapies Inc.

Duopharma Biotech also invested in AZTherapies Inc. ("AZT") in 2020 during the height of the pandemic. AZT had an interesting product in the area focusing on the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's Diseases. This was where the Company has been putting its focus in the course of the last few years because of the lack of any new treatments for neurodegenerative diseases.

AZT completed its Phase III Clinical Trial in December 2020 as planned and has achieved the endpoints for safety. However, the Clinical Trial was badly affected by the pandemic where they had a number of dropouts. As a result, AZT had to do additional studies and expected to be able to commence discussion with the FDA for fast-track approval of its product in the next 12 months. Although the Clinical Trial was impacted by the pandemic in the US, AZT was financially healthy. There was a possibility of a fundraising round in FY2022 but the Company did not plan to participate in that fund-raising exercise.

(10) Manufacturing Strategy 2016 and beyond

Concerning the Manufacturing Strategy, over the period of 2016 to 2022, an estimated Capital Expenditure ("CAPEX") of over RM300 million was spent to upgrade Duopharma Biotech's facilities. The building effervescent facility built in 2017 had now reached full capacity. The Company upgraded its haemo facility in 2017, built warehouses/ sales and marketing offices/ offices in 2018, completed the HAPI facility and K6 warehouse, and completed the Pre-Filled Syringe Line in 2019 for Erysaa. In 2021, the construction of the Company's Oral Solid Dosage ("OSD") facility ("K3") and Biologic facility ("K5") in Klang were delayed as a result of the pandemic / Movement Control Order implemented by the Government and could not be completed on time.

The K3 was expected to complete in 2022.

The Company had a major shutdown in the Bangi facility in November 2021 for upgrading of equipment and restarted the facility in late January 2022 which was per the timeline.

(11) Four-Pronged Strategy

The four-pronged strategy for Duopharma Biotech included (1) Diversification into high-value biologicals and niche products was key; (2) Expanding the range of Ethical and Consumer Healthcare (CHC) product portfolios which would occur on a normal year-on-year basis; (3) Upgrading of manufacturing facilities into world-class assets to allow the Company to improve the level of export; and; (4) Enhance presence in the ASEAN region.

The entire four-pronged strategy was underpinned by the investment in people and in Halal.

(12) Opportunities

Moving forward, some of the opportunities for the Company were highlighted as follows:-

- (a) Increase in allocation for the healthcare sector in budget 2022. The discussion that has taken place since the pandemic, was the level of self-sufficiency of Malaysia moving forward. The Company believed that the healthcare allocation would continue to be strong in the next Malaysia Budget, albeit the healthcare allocation for the pandemic was reduced.
- (b) Extension of Contract Period of the Supply Agreements for the supply of pharmaceutical and/or non-pharmaceutical products to hospitals, clinics and others under the Government of Malaysia for twelve (12) months, until 31 December 2022.
- (c) Insugen Insulin Recombinant Human Formulations under the Ministry of Health's procurement accepted for a period of three (3) years commencing from 17 December 2021 until 16 December 2024 with a total contract value of RM375 million, which was approximately a 50% increase from the current supplies. This was the contract which the Company had enjoyed for the last 5 years.
- (d) Based on the Malaysia Budget announced by the Ministry of Finance ("MOF"), there could be a potential savings of RM 10 million on the Company's tax upon completion of qualifying assets of which the Company was eligible up to FY2024, but the Company would attempt to maximize the savings within FY2022;

- (e) In March 2022, Duopharma Biotech publicly announced its aspiration to achieve Carbon Neutrality by 2030, Net Zero Carbon Emissions by 2050 and replace 50% of Single Use plastics with Biodegradable plastics within the Company's operations by 2026, via Duopharma Biotech's ESG Roadmap targets. The Company was on target in terms of Carbon Neutrality and currently looking into measuring Scope 3 emissions. The matter was still a work in progress where the progress would be reported to the shareholders on an annual basis.
- (f) Various commercialisation of the high-value product in niche therapeutic areas, such as oncology and bio-therapeutics occurred during the year, i.e., the launch of Erysaa to supply EPO to the Government of Malaysia; and the approval of Trastuzumab (Zuhera), an oncology product.
- (g) HAPI facility is in full operational mode with the manufacturing and supply of our first product, Lebreta.
- (h) The Company was in the midst of the technology transfer of a second product in the HAPI plant. Trial batches have been performed in October 2021 and are in the midst of discussion with a partner on the results and process optimisation. The Company expected to be able to sell the second product i.e., Imatinib, in 2022.
- (i) The Covid-19 Sinopharm Vaccine is now widely available at clinics and private hospitals nationwide up to January 2022. In January 2022, the Government announced a ceiling price on the COVID-19 vaccine but the Company did not agree with the ceiling price and appealed against the proposed ceiling price. As a result, the Government had recently revised the ceiling price to RM62 per dose (wholesale), and RM77 per dose (retail) which took effect on 20 May 2022. The Company has now restarted the sales of Sinopharm vaccine in the private sector.

The Company anticipated that there may be a demand for the Sinopharm vaccine for the second half of 2022 arising from potential need for second boosters and the possibility of opening of borders by China.

(8) Challenges

Meanwhile, the challenges faced by the Company were as follows:-

- (a) The residual effect of the Covid-19 pandemic, Russia-Ukraine's Military Conflict and renewed lockdowns in China were as follows:-
 - (i) uncertainties on Endemic led economic environment, in addition to the lockdown in China;
 - (ii) inflationary pressure;
 - (iii) potential supply chain disruption impacting deliveries of API; and
 - (iv) escalation of API price and freight cost, as well as the weakening of the Malaysian Ringgit (MYR) against the United States Dollar (USD). Whilst MYR has performed well relative to the Great Britain Pound (GBP), the European Union currency (Euro), the Australian Dollar (A\$), the Yen, etc., a

large portion of the Company's importation for API is all in USD denominated.

- (b) Implementation of Ceiling Price on Sinopharm Vaccine was a challenge to the Company;
- (c) Fluctuating FOREX impacting production costs;
- (d) Increasing cGMP requirements;
- (e) Differences in regional regulations impact the growth of international businesses;
- (f) Expanding product portfolios (prohibitive BE and clinical costs); and
- (g) The overnight Policy Rate (OPR) was raised by 25 basis points to a new level of 2.00%.

(9) Future Prospect

The GDP growth in Malaysia was forecasted at between 5.5% and 6.5%. With the improvement post opening of the economy, the Company would start to feel impacted by inflationary pressure which the Company would closely monitor.

The Company has been enhancing its portfolio of products in order to further stimulate the strong demand for CHC business as well as its e-commerce potential. The CHC had shown positive growth during the pandemic, especially in the immunity booster products. But with the transfer from the pandemic to the endemic phase, the Company pivots to ensure stability in the sales for CHC as a result of less demand for immunity booster products. The Ethical Classic and Specialty businesses were also set to expand especially from commercial production of Trevive which would be the second cancer molecule to be produced at the Company's HAPI facility.

Some of the Company's focus remained on digital and Environmental, Social and Governance ("ESG") agendas and expected to significantly enhance the Company's contributions to society not only towards making patients in Malaysia better but to making the world a safer, healthier and better place for everyone.

- (e) The Chairman thanked Encik Leonard Ariff for the comprehensive presentation which covered the results of the Company and its future plans. The Chairman then invited Encik Ameenuddin Bin Khali Kasman, the engagement partner of KPMG PLT, to present the Independent Report of the Auditors to the shareholders of the Company in respect of the AFS for the FY2021 as set out on pages 185 to 187 of the AR 2021.

- (f) Encik Ameenuddin informed that KPMG had audited the Financial Statements 2021 of the Company which comprised the Statement of Financial Position of the Company and the Group, the Statement of Profit and Loss and other comprehensive income, Statement in Changes in Equity, and Statement of Cash Flow of the Company and Group, and Notes to the Financial Statements including the summary of significant accounting policies. In KPMG's opinion, the financial statements gave a true and fair view of the financial position of the Company and the Group as at 31 December 2021 and of the Company's financial performance and the cash flows for the year ended and were in accordance with Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act 2016.

AGENDA NO. 2 (Ordinary Resolution 1):

To re-elect Encik Razalee Bin Amin, who retires in accordance with Article 100 of the Company's Constitution and who being eligible, offers himself for re-election.

Encik Razalee Bin Amin's profile was set out in the Notice of the 21st Annual General Meeting as well as on page 205 of the Company's Annual Report 2021. In line with the best practice in corporate governance, the Board has conducted the necessary assessments on Encik Razalee Bin Amin based on the Company's Fit and Proper Policy for the Board of Directors and Senior Management. In this respect, the Board has approved the recommendation of the Nomination and Remuneration Committee that Encik Razalee bin Amin was eligible to stand for re-election.

Ordinary Resolution 1 was proposed by Ms. Ng Su Yee and seconded by Mr Krishnakumara-Reddi. As voting on the resolution was conducted on a poll, the Chairman proceeded to the next Ordinary Resolution.

AGENDA NO. 2 (Ordinary Resolution 2):

To re-elect YBhg Dato' Eisah Binti A. Rahman, who retires in accordance with Article 100 of the Company's Constitution and who being eligible, offers herself for re-election.

Dato' Eisah Binti A. Rahman's profile was set out in the Notice of the 21st Annual General Meeting as well as on page 206 of the Company's Annual Report 2021. In line with the best practice in corporate governance, the Board has conducted the necessary assessments on Dato' Eisah Binti A. Rahman based on the Company's Fit and Proper Policy for the Board of Directors and Senior Management. In this respect, the Board has approved the recommendation of the Nomination and Remuneration Committee that Dato' Eisah Binti A. Rahman was eligible to stand for re-election.

Ordinary Resolution 2 was proposed by Ms. Ng Su Yee and seconded by Mr Krishnakumara-Reddi. As voting on the resolution was conducted on a poll, the Chairman proceeded to the next Ordinary Resolution.

AGENDA NO. 2 (Ordinary Resolution 3):

To re-elect YBhg Dato' Dr. Zaki Morad Bin Mohamad Zaher, who retires in accordance with Article 100 of the Company's Constitution and who being eligible, offers himself for re-election.

Dato' Dr. Zaki Morad Bin Mohamad Zaher's profile was set out in the Notice of the 21st Annual General Meeting as well as on page 207 of the Company's Annual Report 2021. In line with the best practice in corporate governance, the Board has conducted the necessary assessments on Dato' Dr. Zaki Morad Bin Mohamad Zaher based on the Company's Fit and Proper Policy for the Board of Directors and Senior Management. In this respect, the Board has approved the recommendation of the Nomination and Remuneration Committee that Dato' Dr. Zaki Morad Bin Mohamad Zaher was eligible to stand for re-election.

Ordinary Resolution 3 was proposed by Ms. Ng Su Yee and seconded by Mr Krisnakumara-Reddi. As voting on the resolution was conducted on a poll, the Chairman proceeded to the next Agenda.

AGENDA NO. 3 (Ordinary Resolution 4):

To re-elect Puan Amizar Binti Mizuar who was appointed as a Director after the 20th AGM and retires in accordance with Article 106 of the Company's Constitution and who, being eligible, offers herself for re-election.

Puan Amizar Binti Mizuar's profile was set out in the Notice of the 21st Annual General Meeting as well as on page 208 of the Company's Annual Report 2021. In line with the best practice in corporate governance, the Board has conducted the necessary assessments on Puan Amizar Binti Mizuar based on the Company's Fit and Proper Policy for the Board of Directors and Senior Management. In this respect, the Board has approved the recommendation of the Nomination and Remuneration Committee that Puan Amizar Binti Mizuar was eligible to stand for re-election.

Ordinary Resolution 4 was proposed by Ms. Ng Su Yee and seconded by Mr Krisnakumara-Reddi. As voting on the resolution was conducted on a poll, the Chairman proceeded to the next Agenda.

AGENDA NO. 4 (Ordinary Resolution 5):

To approve the payment of the proposed total Directors' fees amounting to RM1,270,000 for the period commencing 22 June 2022 until the conclusion of the next Annual General Meeting of the Company, and further, to authorise the Directors to divide the remuneration among them in such proportions and manner as the Directors may determine.

The Chairman informed that the proposed Directors' fees included provision for the appointment of an additional director to the Board and increase in the membership of the Board Committees. The motion was in line with Section 230(1) of the Companies Act 2016 that requires the fees of directors of a listed company to be approved at a general meeting. The Explanatory Notes on the proposed resolution were set out in the Notice of AGM.

The Chairman informed that Datuk Mohd Radzif has abstained from voting in respect of this resolution and would also ensure that the persons connected to him would abstain from voting in respect of the said resolution at this AGM.

Ordinary Resolution 5 was proposed by Ms. Ng Su Yee and seconded by Mr Krisnakumara-Reddi.

As voting on **Ordinary Resolution 5** was conducted on a poll, the Chairman proceeded to the next Agenda.

AGENDA NO. 5 (Ordinary Resolution 6):

To approve the payment of the proposed total Directors' Remuneration (other than Directors' Fees) up to an amount of RM646,000 for the period from 22 June 2022 until the conclusion of the next AGM of the Company.

The Chairman informed that the motion was in line with the requirements of Paragraph 7.24 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad. The Explanatory Notes on the motion can be found in the Notice of AGM.

The Chairman informed that Datuk Mohd Radzif has abstained from voting in respect of this resolution and would also ensure that the persons connected to him would abstain from voting in respect of the said resolution at this AGM.

Ordinary Resolution 6 was proposed by Ms. Ng Su Yee and seconded by Mr Krisnakumara-Reddi.

As voting on **Ordinary Resolution 6** was conducted on a poll, the Chairman proceeded to the next Agenda.

AGENDA NO. 6 (Ordinary Resolution 7):

To re-appoint Messrs. KPMG PLT as Auditors of the Company and to authorise the Directors to fix their remuneration.

The retiring auditors, Messrs. KPMG PLT, had indicated their willingness to continue in office as auditors. Encik Ameenuddin, the engaging partner of Messrs. KPMG PLT, was present at the Meeting. The Explanatory Notes on the proposed resolution were set out in the Notice of AGM.

The Chairman informed that the Board of Directors recommended to the shareholders for approval on the appointment of KPMG PLT as the external auditors of Duopharma Biotech for 2022 based on the Audit and Integrity Committee's recommendation.

Ordinary Resolution 7 was proposed by Ms. Ng Su Yee and seconded by Mr Krisnakumara-Reddi.

As voting on **Ordinary Resolution 7** was conducted on a poll, the Chairman proceeded to the next Agenda.

AGENDA NO. 7 (Ordinary Resolution 8):

Issuance of New Duopharma Biotech Shares Pursuant to the Dividend Reinvestment Plan that provides the Shareholders of the Company with the Option to Elect to Reinvest their Dividend in New Duopharma Biotech Shares (“Dividend Reinvestment Plan”)

The Chairman informed that this Agenda was tabled as Special Business of the Meeting. The Chairman then tabled the following Ordinary Resolution 8 –

“THAT pursuant to the Dividend Reinvestment Plan as approved by the Shareholders at the Extraordinary General Meeting of the Company held on 31 May 2018, and subject to the approvals of all relevant regulatory authorities or parties being obtained, where required, approval be and is hereby given to the Board of Directors of Duopharma Biotech (“Board”) to allot and issue such number of new Duopharma Biotech Shares from time to time as may be required to be allotted and issued pursuant to the Dividend Reinvestment Plan until the conclusion of the Company’s next annual general meeting, upon terms and conditions and to such persons as the Board may, at its absolute discretion, deem fit and in the best interest of the Company;

THAT the issue price of the said new Duopharma Biotech Shares, which will be determined and fixed by the Board on the price-fixing date to be determined, shall not be more than ten percent (10%) discount to the 5-day volume-weighted average market price (“VWAMP”) of Duopharma Biotech Shares immediately preceding the price-fixing date, of which the VWAMP shall be adjusted ex-dividend before applying the aforementioned discount in fixing the issue price at the material time;

AND THAT the Board be and is hereby authorised to do all such acts and enter into all such transactions, arrangements, deeds and undertakings and to execute, sign and deliver for and on behalf of the Company, all such documents and impose such terms and conditions or delegate all or any part of its powers as may be necessary or expedient in order to implement, finalise and give full effect to the issuance of New Duopharma Biotech Shares pursuant to the Dividend Reinvestment Plan, with full power to assent to any conditions, variations, modifications and/or amendments in any manner, including amendments, modifications, suspension and termination of the Dividend Reinvestment Plan, as the Board may, in its absolute discretion, deem fit and in the best interest of the Company and/or as may be required or permitted by any relevant authorities and to deal with all matters relating thereto.”

As the notice convening this Meeting had been properly given to the shareholders on 28 May 2022, the Chairman declared that the proposed Ordinary Resolution 8 in the Notice of AGM shall be taken as read.

The Dividend Reinvestment Plan was approved by the shareholders at the Extraordinary General Meeting of the Company held on 31 May 2018. The proposed Ordinary Resolution 8, if passed, would give authority to the Board to allot and issue Duopharma Biotech Shares pursuant to the Dividend Reinvestment Plan in respect of dividends declared in the Meeting and subsequently, and such authority shall expire at the conclusion of the next annual general meeting of the Company.

Ordinary Resolution 8 was proposed by Ms. Ng Su Yee and seconded by Mr Krisnakumara-Reddi.

Voting on **Ordinary Resolution 8** was conducted on a poll.

QUESTIONS AND ANSWERS (“Q&A”) SESSION

The Chairman then opened the Q&A session on the audited financial statements of the Company as tabled under Agenda 1 as well as on the proposed resolutions under the rest of the Agenda for the 21st AGM of the Company. The Chairman invited the GMD to first take through the questions submitted by Minority Shareholders Watch Group (“MSWG”) and shareholders prior to this meeting and Management’s responses for the same.

The GMD shared the questions received from MSWG as well as the questions submitted by individual shareholders prior to the Meeting. The GMD clarified that there had been requests that the Company respond to the questions prior to the AGM, but the Company’s policy was to address to Pre-AGM questions at the AGM itself to ensure the responses were given to all shareholders, instead of responding Pre-AGM questions to specific shareholders prior to the AGM.

The GMD highlighted that since the Company had received some replicated questions or questions that had already been posted by other shareholders, the Company had appointed an independent moderator, KPMG Risk and Management Consulting Sdn Bhd., to stream the questions received by the Company and to ensure that the same questions were not addressed repeatedly. The questions and responses were projected on the screen during the meeting as follows:-

(a) Queries from Minority Shareholders Watch Group (MSWG) for FY2021

- Question 1: The Company had preliminary negotiations with the Government to distribute the Russian-manufactured vaccine called Sputnik V. However, the negotiations did not materialise. However, in July 2021, the Company obtained conditional registration approval from Malaysia’s Drug Control Authority (DCA) for Sinopharm, manufactured in China. And in September 2021 it received its first shipments of the vaccine, totalling close to one million doses. Currently, the vaccine (known as Covilo) is available in private clinics and hospitals. (Page 13 of AR 2021)

Question 1(a): What is the total number of COVILLO vaccines which will be brought into the country under the deal with Sinopharm?

Answer: The total number is 963,708 doses of the COVILLO vaccine that was brought in two separate shipments.

Question 1(b): What is the expected revenue from this deal which will be reflected in FYE 2022?

Answer: The expected revenue for FYE2022 based on the revised ceiling price is approximately RM50 million assuming the Company is able to successfully sell all the vaccines.

Question 2: In 2021, the Company began its foray into digital healthcare with Naluri Hidup Sdn. Bhd. ("Naluri"). It began to work with Naluri on apps that could be used with patients it served through its products. Certain healthcare apps in the global market have been approved by the relevant regulators to qualify as digital therapeutics. (Page 17 of AR 2021)

Question 2(a) What is the Company's investment in the area of digital therapeutics in FYE 2021?

Answer: In 2021, the Company invested USD500,000 via Naluri's Series A funding round. This follows an initial investment of USD250,000 via a Simple Agreement for Future Equity (SAFE) made in April 2020. There were no additional investments in 2021 for developing Naluri apps and digital therapeutics and this was ongoing. Apart from investment in digital therapeutics, the Company also invests in digitalisation on several operations such as SAP, Learning Management System, etc. over and above the therapeutics side.

Question 2(b): As digital therapeutics is an area with vast growth potential, what are the Company's plans to ride on this wave of growth?

Answer: The Company plans to strengthen the core and ensure we have the required infrastructure to grow in this area (e.g., database and technologies). We are identifying and evaluating digital health projects. Through partnerships such as Naluri, we will realise projects to add value to the Company and stakeholders.

The Company closely monitors the transformation of new digital therapeutics as the Company was not sure how therapeutics would morph in the Malaysian context. Meantime, the Company manages its database and associated technologies to be able to attend to the future activities of the databases. We continue identifying and evaluating different digital health projects, which include both Business to Business (B2B) and

Business to Consumer (B2C) sectors.

Further, the Company also works with larger customers, such as Lazada and Shopee, to support their e-commerce sites. Currently, the Company has yet to reach a firm landing on the pathways that Malaysia would evolve and how it will develop over time. It was seen that each country overseas tends to have different pathways. The Company is watching closely the development of digital therapeutics, as well as e-commerce

Question 3: The global halal pharmaceutical market continues to grow and is projected to hit USD105 billion in 2024 from USD94 billion in 2019, driven by increasing demand from the Muslim population around the world.

Question 3(a): What are the measures taken by the Company to further penetrate the global Halal pharmaceutical market?

Answer: The described global halal pharma market prospect is based on Muslim pharmaceutical spending. In this view, the Company's ultimate intention is to promote products to the widest range of potential consumers, and religious beliefs should not constrain pharmaceuticals.

Although there are bovine substances in the Company's production of soft gels, the Company would like to be able to move from animal substances to plant-based substances in all its products. Currently, the countries that visibly demonstrate strong demand for halal pharma products are Malaysia, Brunei and Indonesia, i.e., the South East Asia market. A stronger uptake is anticipated due to standards that were being promulgated within the OIC countries under The Standards and Metrology Institute for Islamic Countries (SMIIC), and ultimately, the Company expect SMICC to produce standard to approve and publish the SMIIC OIC standard on Halal with inputs from the OIC member countries. The Company believes that the demand would continue improving as the Company is closely working with SMIC to develop the standards and to support them in terms of public discourse to deliver awareness about the availability and the options of halal pharmaceuticals.

Question 4: Research and Development (R&D) is vital for a pharmaceutical company to stay relevant in the market and continue to be ahead of the curve. It is the lifeblood of the Company and significant investments in this area would ensure that the Company remains profitable moving forward.

Question 4(a): What was the Company's R&D expenses in FYE 2021?

Answer: The Company has been reasonably consistent in its spending on R&D and CAPEX. These are part of the nature of pharmaceuticals industries where the Company continuously spends and reinvests within the business in terms of assets and intellectual properties. Total R&D expenses in FYE 2021 for the Group were 2% to 3% of the total Group's revenue. With the increase in revenue, the absolute MYR value of the investment in R&D has also increased according to the Company's improvement in sales.

Question 4(b): What is the allocated amount for R&D expenses for FYE 2022?

Answer: Similarly, the Company allocated a budget between 2% to 3% of the forecasted Group's revenue for the planned R&D activities in FYE 2022. This budget is not necessarily spent directly in terms of homegrown R&D, but also on the outsourced R&D. The Company outsourced some of its R&D to external contract research organisations to assist in obtaining an optimum balance between what the Company is able to launch for both Ethical and Consumer Healthcare.

Question 5: The Company is constructing an Oral Solid Dosage plant which is targeted for completion in 2022/2023. (Page 23 of AR 2021).

Question 5(a) What is the cost of this plant?

Answer: The total cost, which includes substructure, machines, utilities and consultation, is approximately RM120 million.

Question 5(b) What is the expected capacity of this plant?

Answer: The expected capacity of this plant is expected to contribute at approximately 1.5 billion tablets and 200 million capsules. This facility is expected to replace the Company's old K1 facility in Klang, and the capacity of the said new facility is 50% more than the current K1 facility.

(b) Pre-AGM Questions from Shareholders

Mr. Stephen Lye Tuck Meng

Question 1: Dear Board of Directors, kindly give us some e-vouchers, food vouchers or e-wallet (no discount vouchers please) for being loyal shareholders and attending this meeting. Times are bad now. Please be considerate to us shareholders during these trying times. Thank you.

Answer: As stated in the Administrative Guide for this AGM, the Company will not be distributing any breakfast/lunch packs, door gifts or vouchers, similar to our practice for the last 2 years.

Mr. Kow Lih Shi

Question 2(a): How is the Company's production of the Panadol segment and other correlating products?

Answer: There are 2 types of the analgesic market which consist of ibuprofen and paracetamol. We have the Uphamol brand in the same category. It has a range suitable for both Adults and Children. During this period of shortages, the sales of Uphamol have been improving fairly well to the point where the Company was having difficulty upholding market demand due to production constraints.

Question 2(b): Is the Company facing any shortages of raw materials required for its productions?

Answer: No. There were no shortages of raw materials throughout the pandemic period, whereas during the MCO. However, the Company encountered shortages of individual raw materials which is a regulatory constraint rather than an availability constraint. The Company had carried a higher amount of raw material stocks during the MCO primarily due to the high possibility of the supply chain disruption and the Company had made the right decision as a lot of the raw materials had subsequently increased in prices either to supply shortages or supply chain constraints. The team closely follow up and monitor the supply of raw materials from suppliers to ensure no disruption in the supply of raw materials.

Question 2(c): The availability of Panadol manufactured by other companies tends to be lesser. Are there any comments on this situation?

Answer: We are unable to comment on the competitor's availability in the market. However, as indicated earlier, one of the challenges the Company encountered was the availability of stable labour. While demand increases, production capacity is required to cater for the demand. The team is working very closely in scheduling the production of our paracetamol under the brand name Uphamol.

Question 2(d): Were there any issues of cost efficiency due to lesser production during vaccination period?

Answer: Yes. There was a moderate increase in cost during MCO due to a reduction in production and output. During MCO in 2020, only 50% of employees were allowed to work in factories and due to this, there was a moderate increase in cost during the MCO due to the reduction in production output.

Question 2(e): Why was there less production of drugs during the Covid-19 pandemic and MCO was due to the decrease of demand from the government?

Answer: There were fewer orders for certain common drugs, e.g., antibiotics but. However, medication for Covid-19-related treatment was in high demand, especially for emergency and ICU cases. Whilst the Company is the large producer of Vitamin C in Malaysia and enjoyed the growth of immunity-boosting products, the Company saw the softening of demands for cough and cold products mainly due to the practice of wearing a mask. The Company became healthier during the MCO which led to interesting dynamics in terms of demand for drugs. Any medication produced was used in the treatment of Covid-19 which had increased in demand during the pandemic.

Question 2(f): In which area was the government supply of drugs made a priority?

Answer: During the MCO, priority was given to centres and hospitals that treat Covid-19 patients. There was no extensive demand from the Government in 2021, but the supply of drugs increased as compared to 2020. This helped the Company as the predictability of demand from the public sector allowed the Company to be confident in purchasing raw materials as the offtake by the Government was secured. As reported in the news concerning the issues on shortages of medicines, the GMD believed that it was transient and it was not contributed by Duopharma Biotech as we are able to supply our products into the market as well as meet OTIF targets.

Question 2(g): How does the revision of the Poisons Act and policies in Malaysia as well as the legalisation of banned drugs (referring to cannabis usage in medical) would affect Duopharma?

Answer: We only knew via mainstream news about the review of the Dangerous Drugs Act 1952 which the Government intends to undertake to explore the medicinal use of such plant extracts based on research, including clinical research and data. There is no immediate impact on Duopharma Biotech as products manufactured by the Company under the Dangerous Drugs Act tend to be used in clinical and retail settings. Nevertheless, the

Company would monitor the matter carefully.

Question 2(h): How would research initiatives focusing on plant-based drug production affect current medicine manufacturing? Would it replace the current chemical composition of drugs?

Answer: Yes. The insulin product which the Company represents for Biocon is a biological product with a plant-based source. There was a lot of research going for plant-based alternatives and as part of the sustainability initiatives, the global trend is to go for plant-based ingredients. However, the reliability of supply will depend on the cultivation and harvest of the plants, and the reliability of quality consistency would be achieved by good extraction and standardisation techniques. The Company is not in a traditional medicine sector where all raw materials must be standardised and this includes our Over-the-Counter (OTC) products. Where the Company's OTC products are plant-based, all plant sources are tested for identity, potency and presence of toxic components to ensure safety and product quality to the end consumers.

Question 2(i): How is the R&D fund allocation ratioed against the overall Company's financials?

Answer: Our R&D allocation usually ranges from 2% to 3 % of the overall Group's revenue which was consistent for the last 10 years.

Question 2(j): Other nations globally have taken measures in controlling the outbreak of the monkeypox disease. Would Duopharma undertake any R&D efforts to discover any cure or medication?

Answer: We are not looking into monkeypox vaccines. However, we have an array of products which can relieve the symptoms caused by monkeypox, such as fever, headache, muscle ache, rash, etc. The R&D for vaccine development would usually take 10 to 15 years before a vaccine can be developed. Some of the vaccines which were used during the pandemic were vaccines which already been developed for certain reasons and could also be used for Covid-19.

Question 2(k): There is no end to combating diseases, viruses, and bacteria. How has the Company focused on overcoming this issue?

Answer: Duopharma has a wide range of anti-infectives which include anti-viral, anti-bacterial, anti-fungal, and anti-parasitic medicines. We also develop multiple dosage forms, so apart from the usual tablets, capsules and liquids, we have eye drops, fast disintegrating tablets, and injectables, thus making us a pharma company with the most comprehensive range of anti-infectives on the market. These products have been developed

over a very long period and Duopharma Biotech is very fortunate to be able to address many issues with high demand for these products from the market.

Question 2(l): Are there any periodical reviews done by Duopharma regarding the securitisation of medicine (E.g., seal securities, codes for new implementation)?

Answer: We do look out for new security features which we can use for our products and implement where required. Some examples are tamper-proof seals and holograms. As approved by the Board of Directors, the serialisation for track & trace of our products would be slowly rolled out across the range of our products moving forward. While the Company invest in the securitisation of products, we are conscious of the level of packaging that we use for our products and the Company is looking forward to reducing the amount of packaging for a sustainable future.

Question 2(m): Is Duopharma involved in the research and development of vaccines for the prevention and control of monkeypox?

Answer: We are not looking into monkeypox vaccines. As indicated earlier, we have an array of products which can relieve the symptoms caused by monkeypox, such as fever, headache, muscle ache, rash, etc. We are also discussing with other parties on ranges of vaccines they already have in their portfolio and the necessary announcement would be made if a firm decision is made.

Question 2(n): Does Duopharma take part in international R&D activities?

Answer: We develop products based on Malaysian market needs, including collaborations with overseas partners to come up with new innovative products. Duopharma Biotech's investment in SCM Lifescience Inc was made as we did not have the required skills in handling stem cells in Malaysia. Similarly, the Company collaborate with PanGen Biotech Inc. on EPO, Natco on oncology and Biocon on biologics. These collaborations are the key growth of Duopharma Biotech over the course of 5 to 7 years. We continue working with these parties in R&D and/ or possibly market their products domestically.

Question 2(o): Any financial impact to Duopharma as a result of the increase of minimum wage in Malaysia and ringgit depreciation?

Answer: There would be an impact on the production cost from the new minimum wage. The Company implemented the minimum wage immediately from RM1,200 per month to RM1,500 per month. An increase in production cost is absorbed by the Company and by customers where possible. The

Company have a balanced portfolio where the balance between the private and public market was almost 50-50. While the Company is unable to increase the price of products for the public sector (except during the next round of tender), we are able to push the cost impact on the Company in the private sector. The Management would be looking into increasing the prices for some of the products and would be judicious on the matter as well.

Question 2(p): Is the US dollar the predominant currency in export?

Answer: Most of our export sales are transacted in USD. It represents a natural hedge on the valuation of the USD relative to the MYR.

Question 2(q): Is Duopharma still supplying vaccines to local hospitals post-Covid pandemic?

Answer: The Government only approved our supply of the COVILCO Sinopharm vaccine to the private sector and it is not part of the National vaccination plan.

Mr. Ho Yueh Weng

Question 3(a): To what extent (in RM) has the Company benefitted from the Ministry of Health's procurement by way of direct negotiation? Are there any possibilities of such direct negotiation procurement (DNP) end and how would that impact the Company? What special factor does our Company have to ensure getting such DNP contracts to continue?

Answer: Duopharma Marketing Sdn Bhd, a 100% subsidiary of Duopharma Biotech Berhad was awarded, a Letter of Award from the Ministry of Health ("MOH") for the supply of Biocon's Insugen (recombinant human insulin) via direct negotiation. The contract is for a period of three years commencing from April 29, 2022, until April 28, 2025, with a total value of RM375.17 million which represents over a 50% increase on the average the Company has been supplying over the course of the last 5 years.

There are various factors that both Duopharma Marketing and Biocon Sdn Bhd have to deliver, including good contract performance, which would help to ensure we are considered for such future contracts. Biocon having the second-largest insulin facility in Malaysia also helps us to be considered for future contracts as they were the beneficiaries of the previous Off Take Agreement for 5 years. Because of the importance of Duopharma and Biocon towards the supply of stable insulin over the course of the last 5 years, the Government agreed to continue with the contract, recognising that the product is domestically produced. This would go back to the debate that took place during the pandemic on the

level of self-sufficiency level in Malaysia and to achieve this level of self-sufficiency, Government support is required to support local producers. The Company is having a constant discussion with the Government on the matter where we believed that the Government would introduce a policy to ensure a higher level of self-sufficiency in the Malaysian market as compared to the situation prior to the pandemic.

Question 3(b): Why was there a “Revised Letter of Award” or “Revised LOA”) of 25th April 2022, and is it more advantageous for the Company’s profitability?

Answer: The revised “Letter of Award” was issued by the Government of Malaysia to reflect the tripartite nature of the relationship of parties in the contract i.e., the inclusion of Biocon into the *Surat Setuju Terima*, and there was no change in the price that was quoted. The inclusion was made as the supply of insulin is from the Biocon facility in Johor. There is no impact on the contract’s profitability to the Company.

Mr. Ho Chee Meng

Question 4: Is the online pharmacy business model like in Australia supplying specialist medicines relevant in Malaysia? This will save travelling time for Malaysians living in rural and semi-rural areas.

Answer: Yes, there are already online pharmacy services offered in Malaysia. During the pandemic, the Company saw a tremendous increase in the adoption of the digital healthcare space which includes consultation online or offering online pharmacy services with the delivery of the drugs. The Company believed that the MOH is slowly opening up on the adoption of digital health and moving forward, online options are becoming more readily available.

Mr. Yoong Kwee Soon

Question 5(a): Is the main contributor of revenue from retail sales or government contracts?

Answer: If the export component is taken out from the Company’s revenue, the public sector (i.e., the Government) revenue in 2021 was about 22% and the private sector revenue in 2021 is about 56%. The Company have a balance in term of sales in the Malaysian market.

Question 5(b): Kindly consider providing eVouchers to shareholders as means to boost sales of Duopharma products.

Answer: Thank you for your suggestion. However, as stated in the Administrative Guide for this AGM, the Company will not be distributing any e-vouchers.

Upon Encik Leonard's completion of the presentation of the answers to the questions received prior to the AGM, the Chairman informed that since this morning, the Company had received questions from shareholders into the query box. The Chairman then invited the GMD to take through the questions that the Company had received as streamed by the independent moderator, KPMG Risk and Management Consulting Sdn Bhd. and Management's responses for the same.

Unless otherwise indicated in these minutes, Encik Leonard Ariff had answered the questions on behalf of the Company.

Mr. Lew Tuck Wai

Question 1: Inventories increased by 47% to RM222.192 million in the Financial Year Ended 31 December 2021 with Finished Goods amounting to RM145.857 million (page 154 of AR)

Question 1 (a): Why have Inventories, particularly Finished Goods increased substantially in the Financial Year Ended 31 December 2021?

Answer: Higher stock balance as compared to FYE 2020 was mainly due to the strategy of building up stocks to cater for the year-end Bangi production plant shut down for upgrading and maintenance as part of broader efforts to upgrade our plants to meet GMP requirements. As Bangi plant reopens in January 2022, the Company had started selling down the stocks. Additionally, the COVILO vaccine stocks that came in September 2021 also added to this value. The sales of the COVILO vaccine were progressing until the price mechanism was put in place in January 2022. However, with the adjustment of the ceiling price, the Company hoped to be able to sell the COVILO stocks as well.

Question 1 (b): Will the Group be able to reduce its Finished Goods in Financial Year 2022 as the record for the 1st Quarter 2 of 2022 still shows RM203 million in the value of Inventories?

Answer: Total inventories have reduced to RM203 million as at Q1 2022, from RM222 million as at 31 December 2021. Finished Goods has reduced to RM120 million as at 31 March 2022 as compared to RM146 million as at 31 December 2021. While there was a reduction in Finished Goods, the Company's ability to convert from raw materials to Finished Goods is impacted due to labour constraints in the production section. On an absolute basis, the Management would fully expect the inventory would

reduce but the proviso was that a similar shutdown would be done for our Klang facility and with this, the Company would need to build up 3 months' worth of stocks. For those years without shut down, the Company was able to manage its inventory well.

Question 2: The Group disposed of RM24.598 million of investment in SCM Lifescience Co. Ltd. for a gain of RM16.375 million.

Question 2(a): What are the reason(s) for the disposal?

Answer: When the Company entered into an arrangement with SCM Lifescience Co. Ltd., investments in SCM Lifescience were separated into 2 parts i.e., strategic investment and transactional investment. The Company decided to liquidate a portion of its investment when SCM Lifescience was listed to recoup returns from the non-strategic portion of our shareholding.

Question 2(b): Is SCM Lifescience profitable?

Answer: SCM Lifescience is yet to be profitable as they are currently in the development phase. However, SCM Lifescience is able to raise funding to continue with their research. One stem cell-based hair care product line has been commercialised in Korea while 2 other products are in the late stages of Phase 2 clinical trials. The other product the Company is keen on is a product for atopic dermatitis and would be working with SCM Lifescience on a joint clinical trial. Separately, the Company would be launching SCM Lifescience's Consumer Healthcare stem cell product which was supported by substantial research, at the end of this year. This product would contribute to SCM Lifescience's journey to become a profitable company, assuming we are successful in the sale of the product in Malaysia.

Question 3: The Group has invested in PanGen Biotech Inc, SCM Lifescience Co Ltd and AZTherapies, Inc (page 151 of the Annual Report)

Question 3(a): Are any of these companies listed in any overseas stock exchanges?

Answer: Yes. SCM Lifescience Co. Ltd. and PanGen Biotech Inc. are listed on KOSDAQ in Korea. While AZTherapies is a private company at this stage.

Question 3(b): What are the long-term strategies for investing in these companies?

Answer: Long-term strategy is to have access to new technologies and products. We see it as a low-cost entry point to have access to new technologies and gives us an opportunity to learn from international partners to develop our own internal manufacturing capabilities. The most successful long-term strategy the Company was able to commercialise was the collaboration with PanGen Biotech Inc. i.e., on Erysaa, which was brought

in by PanGen Biotech Inc.

Meanwhile, SCM Lifescience would be on a hair treatment product that the Company is bringing into Malaysia under the CHC section with a launching date at the end of this year. As for the atopic dermatitis product, it would take approximately 2 to 3 years to develop. The GMD highlighted that the Company does not reinvest in these companies if it had secured the right to what the Company required from them and the Company would not be participating in their subsequent series of funding.

Question 4: There is a contracted Capital Expenditure commitment amounting to RM48.286 million in FY2021 (page 182 of the Annual Report) but this is not provided for.

Question 4(a): Please provide details on the budgeted Capital Expenditure of RM48.286 million.

Answer: The budgeted capital expenditures of RM48.286 million are mainly associated with the construction of new production facility K3 and K5 plants as well as upgrading our existing IT infrastructure.

Question 5: The Company has further revised the terms and conditions of its Non-Current Term Loan which stands at RM297.797 million as at 31 December 2021 (Note 13.1, page 156 of AR)

Question 5(a): Kindly share the interest rate after the latest revision of the terms and conditions.

Answer: Arising from the recent OPR increase, the interest rate for the term loan facility has increased from 3.53% to 3.60% per annum to 3.80% p.a. We believed that this is still a competitive rate.

Question 5(b): Is this a fixed rate or a floating rate loan?

Answer: This is a floating rate loan. Hence the slight change or the interest rate is impacted by the OPR.

Question 5(c): What are the repayment terms for this term loan?

Answer: The repayment period of the Bank Islam loan is 9 years, commencing from 2021. For Ambank facility is for a period of 13 years (including 6 years grace period with a repayment period is 7 years, commencing Q3 2023. This was one of the conditions that have changed recently due to the extension of repayment from starting in 2022 to 2023 as a result of the pandemic.

Question 6: The Cash used for the acquisition of Property Plant and Equipment in the Financial Year Ended 31 December 2021 was RM109.362 million and this represents an increase from RM56.111 million spent in FY2020 (page 121 of the AR)

Question 6(a): What are the reasons for the doubling of purchases relating to Property Plant and Equipment in the Financial Year Ended 31 December 2021?

Answer: The increase in our Capital Expenses within FY2021 was mainly from the construction of K3 and K5, and a lot of the equipment for K3 arrived last year and had to be paid for. These are part of our Manufacturing Optimisation Strategy.

Question 6(b): How much is budgeted for Capital Expenditure in FY2022 and what do they relate to?

Answer: For FY2022, we expected the Capital Expenditure to be at approximately RM100 million primarily related to our new production facility in K3 and K5, as well as for the tail end of the Bangi shutdown which was recently done.

Ms. Leong Mei Yoke

Question 7: Kindly highlight why is the share price for Duopharma decreasing in value despite the increasing demand for healthcare products?

Answer: Share price fluctuates according to various factors in the share market which are beyond our control.

Mr Teh Peng Tin

Question 8: What is the total cost of Duopharma Biotech's virtual AGM?

Answer: This cost for virtual AGM would be approximately RM165,000.00 which is more cost-effective as compared to fully physical AGM.

Mr Ho Yueh Weng

Question 9: Why are the major shareholders aggressively disposing of the shares of Duopharma Biotech?

Answer: Shareholders' decision on shareholding is independent of management.

Mr Teoh Hui Han

Question 10(a): Does the increase in minimum wage significantly increase the number of contract workers?

Answer: The Company had adjusted its minimum wage in accordance with the Government policy and it does not lead to a significant increase in the ability to attract workers.

Question 10(b): Does the lack of foreign workers impact production?

Answer: No, it does not impact production adversely. The Company tend to not use foreign workers within Duopharma. But those companies that did use foreign workers are now engaging local workers. We noticed that there are difficulties in recruiting local workers at the moment which the Company is addressing. The minimum wage increases our costs but has not improved the ability to attract workers.

Mr Tan Kim Khuat

Ms Tham Kwan Leng

Ms Ngee Geok Choo

Mr Loo Yew Ming

Mr Ooi Cheng Kooi

Question 11: Kindly provide the shareholders with hard copies of the annual report.

Answer: You may request a copy of the printed Annual Report at <https://tiih.online> by selecting "Request for Annual Report" under "Investor Services". Alternatively, you may also make your request by completing and submitting an online requisition form at Duopharma Biotech Berhad's Corporate Website.

Our share registrar will attend to all requests for the hard copies of the Annual Report upon request.

Mr Choy Yau Kee

Question 12: Will a physical AGM be held in the years moving forward?

Answer: The Company has yet to decide on the mode of holding the AGM moving forward. The Board of Directors will assess on a yearly basis. In this regard, the MCO has forced the Company to hold a fully virtual AGM. With the growing number of foreign shareholders of the Company, virtual meetings would facilitate foreign shareholders' participation in the AGM.

As such, moving forward, the Company's AGM may either be fully virtual or hybrid meeting.

Ms Goh Su Looi @ Goh Pek Leng
Mr Leow Yuk Loong

Question 13: Would the Company consider a better dividend rate in light of the better performance in the post-pandemic environment?

Answer: The Board will decide on the dividend rate on multiple fronts by taking into consideration shareholders' needs, the company's de-gearing strategy as well as to conserve cash as working capital and fund existing business expansion.

Ms Goh Pek Hong

Question 14: When will the Company reward shareholders with bonus issues?

Answer: The Company's most recent bonus issue was in 2021. Currently, we do not have any plan for new bonus issue but the Company reviews the matter on a regular basis and will proceed with bonus issue if suitable.

Mr Loo Yew Ming

Question 15: Does the Board have in place a succession plan for retiring Directors?

Answer: The Board has recently adopted a Succession Plan Policy for Non-Executive Directors. The succession plan is premised on a phased retirement plan and takes into account contingencies situations. The Company is formalising the succession plan and discussing it on a regular basis as an agenda item of the Nomination and Remuneration Committee ("NRC") meeting. The NRC not only discusses on the succession plan for Management but discusses on the Board Succession Plan as well.

Mr Ooi Cheng Kooi

Question 16(a): As the Covid-19 pandemic has tapered, what is the Company's future plan for Covid-19-related medication? Would this kind of medication continue to bring in extra revenue and net profit for the Company?

Answer: We need to look at the available Covid-19 vaccine that we have. The Company also has a wide range of anti-infectives which sells well during the pandemic.

At this stage, no guidance has been provided by the MOH, FDA or related authorities in Europe on whether or not a booster is required to be taken every 6 months. The Company will continue in terms of supplying the Covid-19 vaccine into the market and the opportunity to supply it as a second booster vaccine since many that have taken the first booster have passed 6 months. The Company will continue to closely monitor with respect to guidelines on the second booster or as administration as a regular booster. Nevertheless, the Company would continue investing in anti-infectives but the Company would need to be careful with its focus as many anti-infectives had been developed. Moving forward, the Company would be looking into newer areas rather than relying on older drugs and at the same time maintaining dossiers and manufacturing capability. In view thereof, the Company would plan to pivot away from traditional medicines into biological type of medicines.

Question 16(b): Pursuant to the bonus issue exercise in 2021, the bonus shares given to me were short of 1 unit due to the computation based on 2 different CDS accounts. Kindly clarify.

Answer: The Share Registrar will contact and explain your entitlement after the meeting.

Mr Kow Lih Shi

Question 17: Given the ongoing global geopolitical war, can drugs and medicines be exported to the United States?

Answer: Yes, pharmaceutical products can be exported to the United States provided these products are registered with the US FDA. At this stage, Duopharma is not exporting any products to the United States neither obtaining certification from the United States for our manufacturing facilities, as our focus is ASEAN, regional markets, the Middle East, and selected African countries. The Company would focus on EU certification at the moment.

Mr Yea Sean King

Question 18(a): With regards to the debt taken on to fund the construction of the K3 and K5 facilities, could Duopharma share the expected additional depreciation and startup costs incurred from these expansion projects?

Answer: Upon completion of the Manufacturing Optimisation Strategy, we expect an additional depreciation and other additional costs at approximately RM10 million to RM13 million per annum. It is worthwhile highlighting that we accelerated our depreciation of the K1 facility and building, and a lot of the costs associated with K1 would be fully depreciated once the K3 facility is ready.

Question 18(b): Given Encik Leonard's impressive industry knowledge and performance, it would be in the enlightened interest of the Company to have the pleasure of Encik Leonard's leadership.

How long is the remaining tenure of Encik Leonard? What is the usual tenure renewal for such positions?

Since the following question asked by Mr Yea Sean King was concerning the GMD, the Chairman answered this question.

Answer: The Board of Directors recognised the leadership of Encik Leonard in the Company. For information, Encik Leonard's current contract will run until 14 February 2023. That 6 months prior to the expiry of his contract, the NRC will deliberate on any proposal for renewal of the Group Managing Director's contract and for recommendation to the Board for its approval.

After addressing the above question, the floor was given back to the GMD to address the rest of the live questions from the shareholders.

Question 18(c): In the result for Quarter 1 2022, Duopharma Biotech incurred an RM 8.858 million impairment in inventories.

Kindly shed more light on this item and why it had to be impaired? Is this exercise done during the first quarter annually?

Answer: The Group adopts a stock provision policy of providing for stocks 6 months before the expiry date and on specifically identified items that need to be provided for. This exercise is done quarterly basis and at the end of every quarter, the Company would review its entire inventory portfolio to decide what to impair/ reverse impairment or make provision for. The decision to be made would be discussed with the Company's external auditors as well to be aligned with the Company's policy.

Mr Teoh Hui Han

Question 19: What is the current market share of Duopharma Biotech in Malaysia?

Answer: Duopharma Biotech's overall market share in Malaysia is 7.1% which includes imported medications and locally manufactured medication. In terms of volume, the overall market share of the Company would be much higher boosted by the generic sector.

Mr Phuan Kean Ming

Question 20: What are some of the progress made by Duopharma Biotech on the Environmental, Social and Governance (“ESG”) front?

Answer: The Company had done a lot of work in relation to the ESG front and recognised some fundamental shifts that were occurring in the market. We started doing Sustainability Report much earlier compared to a lot of companies in Malaysia. After Duopharma Biotech's 5-year ESG strategy was presented and approved by the Board of Directors in Q1 2022, the Company made pledges to achieve carbon neutrality by 2030 and Net Zero GHG emission by 2050. Some of the initiatives are to achieve a sustainable supply chain, waste reduction, energy efficiency improvement, water stress/efficiency programs, diversity and inclusion in the workplace, and ISO 37001 Anti Bribery Management System certification for all sites in Duopharma Biotech Berhad. The Scope 1 and 2 Emission was completed, and now the Company had engaged a consultant to assist the Company with the Scope 3 Emission accounting. The GMD highlighted the Company started working towards Net Zero in 2022 to achieve the position in 2050, and the development would be shared with the shareholders annually.

Mr Siah Kim Meng

Question 21(a): What percentage of the Company’s revenue is contributed by the sale of specialty products?

Answer: For FYE 2021, sales of our Ethical Specialty Products contributed approximately 20% to the Group’s total revenue. One of the largest contributors was insulin sales to the Government.

Question 21(b): What are Duopharma’s efforts to improve sales from overseas markets?

Answer: Our model for moving into the international market is multi-fold which includes developing new dossiers/ products that are unique, ensuring manufacturing assets can support the export, and looking at what is manufactured in the markets domestically that is different. For example, the HAPI facility. The Company has launched Letrozole a product for breast cancer which product and already gaining interest from Pakistan and other regional countries as there are very few HAPI facilities available. We hope to increase our exports of unique products rather than commodity products. However, the matter would take some time due to the regulatory process for exports.

Question 21(c): Kindly share the new products that Duopharma Biotech will be launching this year?

Answer: For Ethical, the Company will be launching products in a few therapeutic areas including Respiratory, Sensory, and Hypertension. In fact, there are products that have been developed but were unable to launch due to patent issues. We do design our product range to be able to be the first in the market once the patent expires. As for Consumer Healthcare, there are products under Champs Brand in Q3 2022 and another product in collaboration with SCM Lifescience, at a later point of the year.

Mr Teoh Hui Han

Question 22: Is the selling price adjustment being made in FY2022 to pass down the cost arising from inflation, increase in minimum wage and appreciation of USD on the purchases of raw materials?

Answer: Selling price adjustment is a continuous exercise taking into account impacts on our cost structure. We have adjusted our selling price in 2022 for some ranges of our products but it will be another review of price increases as the Company did not expect a high appreciation of USD against the MYR at the beginning of the year. The Company have to be cautious in recognising we are a generic manufacturer and the benefits of selling generic medications to the consumer are being priced competitively.

Upon completion of the answer to the aforesaid question, the GMD informed that based on the independent moderator's listing of questions, there were no further questions. The list of questions received from the shareholders during the meeting was appended as Annexure III of this Minutes of Meeting. The Chairman announced the closing of the questions and answers session.

AGENDA NO. 8

To transact any other business of which due notice shall have been received.

The Chairman informed that the last Agenda item was to transact any other ordinary business for which due notice has been given in accordance with the Companies Act 2016 and the Company's Constitution. The Company Secretary confirmed that the Company had not received any notice for transaction of other business at this Meeting.

CONDUCT OF POLL VOTING

As there was no other business to be transacted at this Meeting, the Chairman allowed another 10 minutes before declaring the end of the online voting session.

At 11.32 a.m., the Chairman declared that the voting session for the 21st AGM of Duopharma Biotech Berhad through online voting had ended. The Chairman informed that:-

- (a) the Poll Administrator would compile and hand over the poll results to the scrutineers for validation; and
- (b) that the poll results were targeted to be announced at about 11.53 a.m., which was about 20 minutes from the declaration of the end of the voting session.

While waiting for the final results from the scrutineers, the Company's corporate video was screened.

OUTCOME OF THE AGM - POLL RESULTS

At 11.55 a.m., the Chairman called the 21st AGM to order for the declaration of the results.

The polling result which had been verified by the Scrutineers, Scrutineer Solutions Sdn Bhd, was presented on the screen. The Chairman declared that all resolutions as contained in the Notice of the 21st Annual General Meeting of Duopharma Biotech Berhad had been carried. The poll results were as follows:

Resolutions	Vote For		Vote Against		Total Votes	
	No. of Units	%	No. of Units	%	No. of Units	%
Ordinary Resolution 1	662,690,167	99.9318	452,432	0.0682	663,142,599	100.0000
Ordinary Resolution 2	662,860,979	99.9577	280,597	0.0423	663,141,576	100.0000
Ordinary Resolution 3	662,860,446	99.9574	282,463	0.0426	663,142,909	100.0000
Ordinary Resolution 4	662,585,428	99.9159	557,481	0.0841	663,142,909	100.0000
Ordinary Resolution 5	662,482,881	99.9063	621,027	0.0937	663,103,908	100.0000
Ordinary Resolution 6	662,461,887	99.9034	640,721	0.0966	663,102,608	100.0000
Ordinary Resolution 7	662,658,521	99.9272	482,953	0.0728	663,141,474	100.0000
Ordinary Resolution 8	662,880,415	99.9602	263,880	0.0398	663,144,295	100.0000

CLOSE OF MEETING

Before closing the Meeting, the Chairman encouraged the shareholders and proxies to give their feedback on the Virtual AGM by participating in the Post-Virtual AGM Survey to help the Company improve its stakeholder engagement process. The Post-Virtual AGM Survey was made available in a web link and a QR code was shown on the screen.

The Chairman informed that the business for the 21st Annual General Meeting had been concluded and thanked the shareholders for their interest in the Company and for their attendance. The Chairman also thanked the shareholders for all the questions posed and hoped that the answers given provided sufficient clarity. The Chairman then declared the fully virtual 21st Annual General Meeting of Duopharma Biotech Berhad closed at 12.00 noon.

Note: The minutes of the 21st Annual General Meeting of Duopharma Biotech Berhad is available for Members' inspection without charge at the Company's registered office pursuant to Section 48 of the Companies Act 2016.

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
1.	STEPHEN LYE TUCK MENG	Dear BOD - Kindly give us some e-vouchers, food vouchers or e-wallet (no discount vouchers please) for being loyal shareholders and attending this meeting. Times are bad now. Please be considerate to us shareholders during these trying times. TQ	Dear Directors, kindly provide us some e-vouchers, food vouchers or e-wallet (no discount vouchers please) for being loyal shareholders and attending this meeting. Please be considerate to us shareholders during these trying times. Thank you.	Answer to Questions 1 and 5(b), Pages 24 and 30	As stated in the Administrative Guide for this AGM, the Company will not be distributing any breakfast/lunch packs, door gifts or vouchers, similar to our practice for the last 2 years.
2	LUM PECK WAN	Dear Honourable Chairman & Board of Directors, We appeal to your good selves & generosity to reward attend this d us your loyal shareholders with E-Wallets E Vouchers or Food vouchers for making the effort & taking the time to attend this virtual AGM. Tq !			
3	JUSTIN CHAN KEN YIP	Dear Honourable Chairman & Board of Directors, We appeal to your kind selves & generosity to reward us your loyal shareholders with E-Wallets, E-Vouchers and /or Food Vouchers, for			

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		<p>making the effort & taking the time to attend this AGM.</p> <p>We look forward to receiving them as they will help defray the high costs of living escalated by the Covid19 pandemic. Thank you.</p> <p>We were GREATLY DISAPPOINTED that we were not given any rewards last year. We hope NOT TO BE DISAPPOINTED AGAIN !!!</p>			
4	CHAN CHEE KONG	<p>Dear Honorable Chairman & Board of Directors,</p> <p>We appeal to your kindnesses & generosity to reward us your loyal shareholders with E-Wallets, E-Vouchers and /or Food Vouchers, for making the effort & taking the time to attend this AGM. GREATLY DISAPPOINTED that none were given last year ... HOPE WE WILL NOT BE LET DOWN AGAIN THIS YEAR!!!!</p> <p>Look forward to receiving THE EXCELLENT door gifts! Thank you</p>			

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
5	LAU CHUAN HOOI	Will the Board consider giving door gifts such e-voucher or e-wallets for those participating in this Agm as a token of appreciation?			
6	THAVARAJAN A/L MUTHIAH PILLAI	Dear Sir, Please give us some vouchers to buy your duopharma products as loyal shareholders. Thank you. .			
7	MOHD TAHIR BIN MAULUT	Saya dengan rendah hati memohon BOD untuk memberikan e-wallet atau e-baucar kepada para hadirin sebagai tanda penghargaan. Saya percaya jumlah token adalah kecil, boleh diurus dan dalam perbelanjaan anggaran tahunan.			
8	TAN MEI TENG	got gift?			

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
9	LEE CHONG SING	Good morning Mr.Chairman and board of directors.I wish to request for Rm30 Touch-n-Go E-wallet as a token of appreciation to shareholders who attending this Agm.Tqvm in advance for your kind consideration.			
10	THANG YEEN PENG	Please approve some form of e-wallet to shareholders attending this agm. thank you in advance.			
11	PORAVI A/L S P SITHAMBARAM PILLAY	Good morning. My full support for all the resolutions. Our Company is in good hands. Thank you for taking good care of loyal shareholders participating and voting in this RPV today.			
12	LEONG MEI YOKE	Any doorgift for attending the AGM today? Duopharma always don't give doorgift; give something to your shareholders.			

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
13	MONO KARI A/P SOKKALINGAM	<p>Good morning. My full support for all the resolutions. Our Company is in excellent capable hands.</p> <p>Thank you for taking good care of loyal shareholders participating and voting in this RPV today..</p>			
14	LUM PECK WAN	<p>Dear Honorable Chairman & Board of Directors, We appeal to your kindnesses & generosity to reward us your loyal shareholders with E-Wallets, E-Vouchers and /or Food Vouchers, for making the effort & taking the time to attend this AGM. GREATLY DISAPPOINTED NONE WERE GIVEN LAST 3 YEARS !!! HOPE NOT TO BE DISAPPOINTED AGAIN THIS YEAR !!!!!!! Look forward to receiving YOUR EXCELLENT DOORGIFTS this time ! Thank you.</p>			

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
15	REEVANASH A/L PORAVI	<p>Good morning. My favorable votes for all the resolutions. Our Company is in the most competent hands.</p> <p>Thank you for taking good care of hard core loyal shareholders participating and voting in this RPV today..</p>			
16	CHAN NGUN FONG	This is the 3rd year the Company is holding its meeting virtually. Please do not brush our requests aside for ewallet top ups as token of appreciation as we do need to register, log in and listen to the meeting proceedings. Be kind to your loyal shareholders. Thank you.			
17	CHOY YAU KEE	CHAIRMAN, when are you going to resign to account for the deep fall in the share price of the company???			
18	GOH TENG CHING	A doorgift for those attending the AGM is much appreciated thks.			
19	TEH SUE LENG	I'm a long time and loyal shareholder of the company. I would like to			

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		request that the board kindly consider giving shareholder with e- voucher as a token of appreciation for attending today's RPV. Thank you			
20	GAN SIEW KEEN	Share price drop too much.any e voucher			
21	NG SOOK LUAN	please give us vouchers, ty			
22	LEE SUAN BEE	Can the company give shareholders with e— wallet as a token of appreciation for attending today's RPV			
23	LUM CHOONG YING	BOD kindly consider to reward shareholders with e-products vouchers to purchase the products online etc. Thanks			
24	NG YING SENG	Dear directors, we need voucher to survive. Please give us voucher and tyvm.			
25	CHAN AH MOI	Please give door gift.			
26	TEY YOOK LAN	are the company will consider to provide door gift ,e-voucher (e wallet T& G) to all attendance shareholders/proxies, thank you			

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
27	LAU ATI @ LAU CHUAN TENG	Please consider giving e-voucher to participating shareholders as token of appreciation for effort and cost of attending and supporting the company Thank you.			
28	TEY CHIN	are the company will consider to provide door gift ,e-voucher (e wallet T& G) to all attendance shareholders/proxies. Thank you.			
29	LIM PIN YEONG	Can the company consider giving Door gift or eVoucher to shareholders participatinn in this virtual AGM? MSM, Sime Darby Plantation, FGV, Kawan Food sent door gift via courier to shareholders. You can also emulate them. Thank you.			
30	LEE KWAI YOONG	Hi Good Day. With your rumbustious ideas and plans, shareholders are expecting a Door Gift/E-voucher in this virtual AGM. It is not a compulsion but as a gesture of Gratitude to the shareholders"" support. SOAR HIGH. Thank you			

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
31	TAN BEE HOON	Any door gifts for shareholders			
32	RONALD DANKER	Any door gifts for shareholders			
33	GOH PEK HONG	Good morning to BoD, When will the company reward shareholders with bonus issue? Will shareholders be rewarded with doorgift for attending this agm remotely? Tq.			
34	NGEE GEOK CHOO	Good morning to Tan Sri chairman director s and all the others, I am MDM Ngee.please consider to distribute some e vouchers or e wallets to today's attendees as a token of appreciation upon the effort and support of the company. Kindly send me a print copy of the latest annual report to my registered address.Thank You.			
35	LOO YEO MING	Kindly reconsider giving doorgift as token of appreciation for our votes to the directors fees etc > Better to give to shareholders than receive all the passed resolution.			

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
36	LIEW THYE	kindly consider to give e-voucher to the shareholders whose participate this virtual AGM meeting as token appreciation			
37	LOO YEO MING	Any succession planning to replace retiring directors so that they can reward the shareholders by giving increasing dividends, bonus issue, give extra shares, doorgift eg evoucher, ewallet etc,,,, To assure that BOD take care of VALUED shareholders.			
38	LEE TUCK FEONG	Hi Good morning. Shareholders are anticipating the annual AGM Door gift/E-Voucher. Do not vex them over this expectation. Be grateful to the shareholders and a gesture of goodwill for their support. SOAR Higher than your peers. Thank you			
39	LEE SZE TENG	Hi Good morning. BOD , kindly distribute Door gift of your company""s product for the shareholders perusal in this virtual AGM			

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
40	LEE SZE FAYE	Hi. Shareholders are expecting to peruse the company"s products in this annual virtual AGM as Door Gifts. Do not repress the melancholic shareholders . Listen to the innuendoes. SOAR HIGH .Not the clowns. Thank you			
41	LEE TUCK FEONG	Do Not vex the shareholders for their support of the shareholders. Listen to their metaphors. You can distribute door gifts to the shareholders attending this AGM to the contrary of your notice sent in your AR. Our time is valuable and priceless Do not be Clowns. SOAR Higher than your peers. Thank you.			
42	LUM PECK WAN	VERY DISAPPOINTED NO DOOR GIFTS AGAIN !!!!			
43	CHAN CHEE KONG	No doorgifts AGAIN !! That is NOT GOOD AT ALL !!! Make sure give us HIGHER & BETTER DIVIDENDS AND/OR BONUS ISSUES !!			

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
44	TAN TENG CHEE	Evoucher please.thank you God bless			
45	TAN KIM KHUAT	Pls send a printed report to my puchong address	Kindly provide the shareholders with hard copies of the annual report.	Answer to Question 11, Page 35	You may request a copy of the printed Annual Report at https://tiih.online by selecting “Request for Annual Report” under “Investor Services”. Alternatively, you may also make your request by completing and submitting an online requisition form at Duopharma Biotech Berhad’s Corporate Website. Our share registrar will attend to all requests for the hard copies of the Annual Report upon request.
46	THAM KWAN LENG	Please send me an integrated printed Annual Report of the company. Thank you.			
47	OOI CHENG KOOI	I am requesting a set of 2021AGM annual report. please send to me asap. Thank you.			
48	KOW LIH SHI LEOW YUK LOONG HOO LEY BENG LAI KIM LOONG	(a) How was company in produce panadol sectment and correlating products? (b) Are we facng shortages on raw material?	(a) How is the Company’s production of the Panadol segment and other correlating products? (b) Is the Company facing any shortages of raw materials required for its productions?	Answers to Questions 2(a) to 2(q) on pages 25 to 29	(a) We have Uphamol brand in the same category. It has a range suitable for Adults and Children. (b) No. The team closely follow up and monitor the supply of raw materials from suppliers to ensure no disruption in supply of raw material.

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		<p>(c) Some happen less product panadol in retail market?</p> <p>(d) Is the issue on cost efficiency of less production during peak period of vaccine time less production happens?</p> <p>(e) During MCO and covid case on quarantine High cast. The cluster facing less medicine on not sufficiency to distribute, are thus happen less order maked by government sectment?</p> <p>(f) Where government supply as priority in concern?</p>	<p>(c) The availability of Panadol manufactured by other companies tend to be lesser. Are there any comments on this situation?</p> <p>(d) Were there any issues of cost efficiency due to lesser production during vaccination period?</p> <p>(e) Why were there less production of drugs during the Covid-19 pandemic and MCO was due to the decrease of demand from the government?</p> <p>(f) In which area was the government supply of drugs made a priority?</p>		<p>(c) We can't comment on our competitor's availability in the market.</p> <p>(d) Yes. There was a moderate increase in cost during MCO due to a reduction in production and output. During MCO in 2020, only 50% of employees were allowed to work in factories and due to this, there was a moderate increase in cost during the MCO due to the reduction in production output.</p> <p>(e) There were less orders for certain common drugs, e.g., antibiotics but. However, medication for Covid-19 related treatment was in high demand especially for emergency & ICU cases.</p> <p>(f) Priority was given to centres and hospitals that treat Covid-19 patients.</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		<p>(g) How was the chemical and poisons act Malaysia going revise and also planting poisoning overseas are legally, does Duopharma will affect of that impact?</p> <p>(h) Some programme research abstract from plant of poisons, are going reliable replace chemical mixture?</p>	<p>(g) How does the revision of Poisons Act and policies in Malaysia as well as legalisation of banned drugs (referring to cannabis usage in medical) would affect Duopharma?</p> <p>(h) How would research initiatives focusing on plant-based drug production affect current medicine manufacturing? Would it replace current chemical composition of drugs?</p>		<p>(g) We only know via mainstream news about the review of the Dangerous Drugs Act 1952 which the Government intends to undertake to explore medicinal use of such plant extracts based on research, including clinical research and data. There is no immediate impact to Duopharma</p> <p>(h) Yes. The insulin product which the Company represents for Biocon is a biological product with a plant-based source. There was a lot of research going for plant-based alternatives and as part of the sustainability initiatives, the global trend is to go for plant-based ingredients. However, the reliability of supply will depend on the cultivation and harvest of the plants, and the reliability of quality consistency would be achieved by good extraction and standardisation techniques. The Company is not in a traditional medicine</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		<p>(i) How was R&D fund allocation in company overall financial ratio?</p> <p>(j) The monkey pox, oversea have implement medicine. Does company will doing follow up research for medicine, as ready for Malaysia participate in researching too?</p> <p>(k) In microbiology, there is no ending point of disease as well as viruses' bacteria. Does company more</p>	<p>(i) How is the R&D fund allocation ratioed against overall Company's financials?</p> <p>(j) Other nations globally have taken measures in controlling the outbreak of the monkeypox disease. Would Duopharma undertake any R&D efforts to discover any cure or medication?</p> <p>(k) There is no end in combating diseases, viruses, and bacteria. How has the Company focused on overcoming this issue?</p>		<p>sector where all raw materials must be standardised and this includes our Over-the-Counter (OTC) products. Where the Company's OTC products are plant-based, all plant sources are tested for identity, potency and presence of toxic components to ensure safety and product quality to the end consumers.</p> <p>(i) Our R&D allocation usually ranges at 2% to 3 % to the overall Group's revenue.</p> <p>(j) We are not looking into monkeypox vaccines. However, we have an array of products which can relief the symptoms caused by monkeypox, such as fever, headache, muscle ache, rash, etc.</p> <p>(k) Duopharma has a wide range of anti-infectives which include anti-viral, anti-bacterial, anti-fungal, and anti-parasitic medicines. We also develop</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		<p>focus on that section for contribution in medicines?</p> <p>(l) The securities of medicine are highly focus in international. Does company will yearly review on that particular? E.g., seal securities, codes for new implement?</p> <p>(m) Could company produce medicine for monkey pox and research team for new disease for company participate?</p>	<p>(l) Are there any periodical reviews done by Duopharma regarding the securitisation of medicine (E.g., seal securities, codes for new implement)?</p> <p>(m) Is Duopharma involved in the research and development of vaccines for the prevention and control of monkeypox?</p>		<p>multiple dosage forms, so apart from the usual tablets, capsules and liquids, we have eye drops, fast disintegrating tablets, and injectables, thus making us a pharma company with the most comprehensive range of anti-infectives on the market. These products have been developed over a very long period and Duopharma Biotech is very fortunate to be able to address many issues with high demand for these products from the market.</p> <p>(l) We do look out for new security features which we can use for our products and implement where required. Examples are: tamper-proof seals, holograms. It's in our plan to look into serialisation for track & trace of our products.</p> <p>(m) We are not looking into monkeypox vaccines. As indicated earlier, we have an array of products which can</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		(n) Does company participate in medicines World class researching? In microbiology, there is no ending point of disease as well as viruses bacteria. Does company more focus on that section for contribution in medicines?	(n) Does Duopharma take part in international R&D activities?		<p>relieve the symptoms caused by monkeypox, such as fever, headache, muscle ache, rash, etc. We are also discussing with other parties on ranges of vaccines they already have in their portfolio and the necessary announcement would be made if a firm decision is made.</p> <p>(n) We develop products based on Malaysian market needs, including collaborations with overseas partners to come up with new innovative products. Duopharma Biotech's investment in SCM Lifescience Inc was made as we did not have the required skills in handling stem cells in Malaysia. Similarly, the Company collaborate with PanGen Biotech Inc. on EPO, Natco on oncology and Biocon on biologics. These collaborations are the key growth of Duopharma Biotech over the course of 5 to 7 years. We continue working with these</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		(o) The new wages and also ringgit exchange rate (ringgit value getting low compare to past years) does this become challenges to company financial and how was company overcome the cost increasing?	(o) Any financial impact to Duopharma as a result of the increase of minimum wage in Malaysia and ringgit depreciation?		<p>parties in R&D and/ or possibly market their products domestically.</p> <p>(o) There would be an impact on the production cost from the new minimum wage. The Company implemented the minimum wage immediately from RM1,200 per month to RM1,500 per month. An increase in production cost is absorbed by the Company and by customers where possible. The Company have a balanced portfolio where the balance between the private and public market was almost 50-50. While the Company is unable to increase the price of products for the public sector (except during the next round of tender), we are able to push the cost impact on the Company in the private sector. The Management would be looking into increasing the prices for some of the products and would be judicious on the matter as well.</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		<p>(p) The export product occur, only depending USD exchange?</p> <p>(q) Company could obtain from government support of local hospital and past cluster covid supply?</p> <p>(r) Could drug and medicine. Malaysia export to USA. Since war happening.. Now?</p>	<p>(p) Is the US dollar the predominant currency in export?</p> <p>(q) Is Duopharma still supplying vaccines to local hospitals post-Covid pandemic?</p> <p>(r) Given the ongoing global geopolitical war, can drugs and medicines be exported to the United States?</p>		<p>(p) Most of our export sales are transacted in USD. It represents a natural hedge on the valuation of the USD relative to the MYR.</p> <p>(q) The Government only approved our supply of the COVILLO Sinopharm vaccine to the private sector and it is not part of the National vaccination plan.</p> <p>(r) Yes, pharmaceutical products can be exported to the United States provided these products are registered with the US FDA. At this stage, Duopharma is not exporting any products to the United States neither obtaining certification from the United States for our manufacturing facilities, as our focus is ASEAN, regional markets, the Middle East, and selected African countries. The Company would focus on EU certification at the moment.</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
49	HO YUEH WENG	(a) To what extent, in Ringgit terms, has our Co. benefited under the Ministry of Health's procurement by way of direct negotiation, and what are the possibility of such direct negotiation procurement (DNP) end and its impact? What special factor our Co. has to ensure getting such DNP contracts continue?	(a) To what extent (in RM) has the Company benefitted from the Ministry of Health's procurement by way of direct negotiation? Are there any possibilities of such direct negotiation procurement (DNP) end and how would that impact the Company? What special factor does our Company have to ensure getting such DNP contracts to continue?	Answers to Questions 3(a) to 3(b) on pages 29 to 230	<p>(a) Duopharma Marketing Sdn Bhd, a 100% subsidiary of Duopharma Biotech Berhad was awarded, a Letter of Award from the Ministry of Health ("MOH") for the supply of Biocon's Insugen (recombinant human insulin) via direct negotiation. The contract is for a period of three years commencing from April 29, 2022, until April 28, 2025, with a total value of RM375.17 million which represents over a 50% increase on the average the Company has been supplying over the course of the last 5 years.</p> <p>There are various factors that both Duopharma Marketing and Biocon Sdn Bhd have to deliver, including good contract performance, which would help to ensure we are considered for such future contracts. Biocon having the second-largest insulin facility in Malaysia also helps us to be considered for future contracts as they were</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
					<p>the beneficiaries of the previous Off Take Agreement for 5 years. Because of the importance of Duopharma and Biocon towards the supply of stable insulin over the course of the last 5 years, the Government agreed to continue with the contract, recognising that the product is domestically produced. This would go back to the debate that took place during the pandemic on the level of self-sufficiency level in Malaysia and to achieve this level of self-sufficiency, Government support is required to support local producers. The Company is having a constant discussion with the Government on the matter where we believed that the Government would introduce a policy to ensure a higher level of self-sufficiency in the Malaysian market as compared to the situation prior to the pandemic.</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		(b) Why was there a “Revised Letter of Award” or “Revised LOA”) of 25th April 2022, and is it more advantageous for our Co's profitability?	(b) Why was there a “Revised Letter of Award” or “Revised LOA”) of 25th April 2022, and is it more advantageous for the Company's profitability?		(b) The revised “Letter of Award” was issued by the Government of Malaysia to reflect the tripartite nature of the relationship of parties in the contract i.e., the inclusion of Biocon into the Surat Setuju Terima, and there was no change in the price that was quoted. The inclusion was made as the supply of insulin is from the Biocon facility in Johor. There is no impact on the contract's profitability to the Company.
50	HO CHEE MENG	Is the online pharmacy business model like in Australia supplying specialist medicines relevant in Malaysia? This will save traveling time for Malaysians living in rural and semi-rural areas.	Is the online pharmacy business model like in Australia supplying specialist medicines relevant in Malaysia? This will save travelling time for Malaysians living in rural and semi-rural areas.	Answer to Question 4 page 30	Yes, there are already online pharmacy services offered in Malaysia. During the pandemic, the Company saw a tremendous increase in the adoption of the digital healthcare space which includes consultation online or offering online pharmacy services with the delivery of the drugs. The Company believed that the MOH is slowly opening up on the adoption

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
					of digital health and moving forward, online options are becoming more readily available.
51	YOONG KWEE SOON	<p>(a) Is our company's revenue dependent more on retail sales or government contract?</p> <p>(b) I think by giving evouchers to shareholders to purchase our products is a very good way to promote our own products and boost our retail sales?</p>	<p>(a) Is the main contributor of revenue from retail sales or government contracts?</p> <p>(b) Kindly consider providing eVouchers to shareholders as means to boost sales of Duopharma products.</p>	Answers to Questions 5(a) to 5(b) on page 30	<p>(a) If the export component is taken out from the Company's revenue, the public sector (i.e., the Government) revenue in 2021 was about 22% and the private sector revenue in 2021 is about 56%. The Company have a balance in term of sales in the Malaysian market.</p> <p>(b) Thank you for your suggestion. However, as stated in the Administrative Guide for this AGM, the Company will not be distributing any e-vouchers.</p>
52	LEW TUCK WAI MOHD TAHIR BIN MAULUT	(1) The Group disposed of RM24.598 million of investment in SCM Lifescience Co. Ltd. for a gain of RM16.375 million.	(1) Inventories increased by 47% to RM222.192 million in the Financial Year Ended 31 December 2021 with Finished Goods amounting to	Answers to Questions 1 to 6 on pages 31 to 34	

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		(a) Why has Inventories, in particular Finished Goods increased substantially in FY2021?	<p>RM145.857 million (page 154 of AR)</p> <p>(a) Why have Inventories, particularly Finished Goods increased substantially in the Financial Year Ended 31 December 2021?</p>		<p>(a) Total inventories have reduced to RM203 million as at Q1 2022, from RM222 million as at 31 December 2021. Finished Goods has reduced to RM120 million as at 31 March 2022 as compared to RM146 million as at 31 December 2021. While there was a reduction in Finished Goods, the Company's ability to convert from raw materials to Finished Goods is impacted due to labour constraints in the production section. On an absolute basis, the Management would fully expect the inventory would reduce but the proviso was that a similar shutdown would be done for our Klang facility and with this, the Company would need to build up 3 months' worth of stocks. For those years without shut down, the Company was able to manage its inventory well.</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		<p>(b) Will the Group be able to reduce its Finished Goods in FY2022 as the 1st Quarter 2022 still show RM203 million in Inventories value?</p> <p>(2) The Group disposed of RM24.598 million of investment in SCM</p>	<p>(b) Will the Group be able to reduce its Finished Goods in Financial Year 2022 as the record for the 1st Quarter 2 of 2022 still shows RM203 million in the value of Inventories?</p> <p>(2) The Group disposed of RM24.598 million of investment in SCM</p>		<p>(b) Total inventories have reduced to RM203 million as at Q1 2022, from RM222 million as at 31 December 2021. Finished Goods has reduced to RM120 million as at 31 March 2022 as compared to RM146 million as at 31 December 2021. While there was a reduction in Finished Goods, the Company's ability to convert from raw materials to Finished Goods is impacted due to labour constraints in the production section. On an absolute basis, the Management would fully expect the inventory would reduce but the proviso was that a similar shutdown would be done for our Klang facility and with this, the Company would need to build up 3 months' worth of stocks. For those years without shut down, the Company was able to manage its inventory well.</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		<p>Lifescience Co. Ltd. for a gain of RM16.375 million.</p> <p>(a) What are the reason(s) for the disposal?</p> <p>(b) Is SCM Lifescience profitable?</p>	<p>Lifescience Co. Ltd. for a gain of RM16.375 million.</p> <p>(a) What are the reason(s) for the disposal?</p> <p>(b) Is SCM Lifescience profitable?</p>		<p>(a) When the Company entered into an arrangement with SCM Lifescience Co. Ltd., investments in SCM Lifescience were separated into 2 parts i.e., strategic investment and transactional investment. The Company decided to liquidate a portion of its investment when SCM Lifescience was listed to recoup returns from the non-strategic portion of our shareholding.</p> <p>(b) SCM Lifescience is yet to be profitable as they are currently in the development phase. However, SCM Lifescience is able to raise funding to continue with their research. One stem cell-based hair care product line has been commercialized in Korea while 2 other products are in the late stages of Phase 2 clinical trials. The other product the Company is keen on is a product for atopic dermatitis and would be working with SCM</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		<p>(3) The Group had invested in PanGen Biotech Inc, SCM Lifescience Co Ltd and AZTheraphies, Inc (page 151 of the AR)</p> <p>(a) Are any of this companies listed in any overseas stock exchanges?</p> <p>(b) What are the long-term strategies for investing in these companies?</p>	<p>(3) The Group has invested in PanGen Biotech Inc, SCM Lifescience Co Ltd and AZTheraphies, Inc (page 151 of the Annual Report)</p> <p>(a) Are any of these companies listed in any overseas stock exchanges?</p> <p>(b) What are the long-term strategies for investing in these companies?</p>		<p>Lifescience on a joint clinical trial. Separately, the Company would be launching SCM Lifescience's Consumer Healthcare stem cell product which was supported by substantial research, at the end of this year. This product would contribute to SCM Lifescience's journey to become a profitable company, assuming we are successful in the sale of the product in Malaysia.</p> <p>(a) Yes. SCM Lifescience Co. Ltd. and PanGen Biotech Inc. are listed on KOSDAQ in Korea. While AZTheraphies is a private company at this stage.</p> <p>(b) Long-term strategy is to have access to new technologies and products. We see it as a low-cost entry point to have access</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
					<p>to new technologies and gives us an opportunity to learn from international partners to develop our own internal manufacturing capabilities. The most successful long-term strategy the Company was able to commercialise was the collaboration with PanGen Biotech Inc. i.e., on Erysaa, which was brought in by PanGen Biotech Inc.</p> <p>Meanwhile, SCM Lifescience would be on a hair treatment product that the Company is bringing into Malaysia under the CHC section with a launching date at the end of this year. As for the atopic dermatitis product, it would take approximately 2 to 3 years to develop. These are the investments with proceeds. The GMD highlighted that the Company do not reinvest in these companies if it had secured the right to what the Company required from them and the Company would not be</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		<p>(4) The Capital Expenditure commitment contracted but not provided for amounted to RM48.286 million in FY2021 (page 182 of AR).</p> <p>(a) What is main Capex of the RM48.286 million budgeted for?</p> <p>(5) The Company has further revised the terms and conditions its Non-Current Term Loan which stands at RM297.797 million as at 31 Dec 2021 (Note 13.1, page 156 of AR)</p> <p>(a) What is the interest rate after the latest revision of the T&C?</p>	<p>(4) There is a contracted Capital Expenditure commitment amounting to RM48.286 million in FY2021 (page 182 of the Annual Report) but this is not provided for.</p> <p>(a) Please provide details on the budgeted Capital Expenditure of RM48.286 million.</p> <p>(5) The Company has further revised the terms and conditions of its Non-Current Term Loan which stands at RM297.797 million as at 31 December 2021 (Note 13.1, page 156 of AR)</p> <p>(a) Kindly share the interest rate after the latest revision of the terms and conditions.</p>		<p>participating in their subsequent series of funding.</p> <p>(a) The budgeted capital expenditures of RM48.286 million are mainly associated with the construction of new production facility K3 and K5 plants as well as upgrading our existing IT infrastructure.</p> <p>(a) Arising from the recent OPR increase, the interest rate for the term loan facility has increased from 3.53% to 3.60% per annum</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		<p>(b) Is this a fixed rate or floating rate loan?</p> <p>(c) What is the repayment terms for this term loan?</p> <p>(6) The Cash used for acquisition of PPE in FY2021 was RM109.362 million an increase from RM56.111 million spent in FY2020 (page 121 of the AR)</p>	<p>(b) Is this a fixed rate or a floating rate loan?</p> <p>(c) What are the repayment terms for this term loan?</p> <p>(6) The Cash used for the acquisition of Property Plant and Equipment in the Financial Year Ended 31 December 2021 was RM109.362 million and this represents an increase from RM56.111 million spent in FY2020 (page 121 of the AR)</p>		<p>to 3.80% p.a. We believed that this is still a competitive rate.</p> <p>(b) This is a floating rate loan. Hence the slight change or the interest rate is impacted by the OPR.</p> <p>(c) The repayment period of the Bank Islam loan is 9 years, commencing from 2021. For Ambank facility is for a period of 13 years (including 6 years grace period with a repayment period is 7 years, commencing Q3 2023. This was one of the conditions that have changed recently due to the extension of repayment from starting in 2022 to 2023 as a result of the pandemic.</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		<p>(a) What are the reason(s) for the doubling of PPE purchases in FY2021?</p> <p>(b) How much is budgeted for Capex in FY2022 and what are they mainly spent on?</p>	<p>(a) What are the reasons for the doubling of purchases relating to Property Plant and Equipment in the Financial Year Ended 31 December 2021?</p> <p>(b) How much is budgeted for Capital Expenditure in FY2022 and what do they relate to?</p>		<p>(a) The increase in our Capital Expenses within FY2021 was mainly from the construction of K3 and K5, and a lot of the equipment for K3 arrived last year and had to be paid for. These are part of our Manufacturing Optimisation Strategy.</p> <p>(b) For FY2022, we expected the Capital Expenditure to be at approximately RM100 million primarily related to our new production facility in K3 and K5, as well as for the tail end of the Bangi shutdown which was recently done.</p>
53	YEA SEAN KING AHMAD MARZUKI ABD RAZAK	(a) earlier it was mentioned that the company is taking on debt to fund certain capex (plant k3, K5). May i know what is the expected additional depreciation and startup costs to be incurred from these expansion projects?	(a) With regards to the debt taken on to fund the construction of the K3 and K5 facilities, could Duopharma share the expected additional depreciation and startup costs incurred from these expansion projects?	Answers to Questions 18(a) to 18(c) on pages 37 to 38	(a) Upon completion of the Manufacturing Optimisation Strategy, we expect an additional depreciation and other additional costs at approximately RM10 million to RM13 million per annum. It is worthwhile highlighting that we accelerated our depreciation of the K1 facility and building, and a lot of the costs associated with K1 would

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		<p>(b) i am impressed with En. Leonard's knowledge on the industry, his execution and performance. please may i know how long more can we have the pleasure of En leonard's stewardship of the company? when is his employment contract due for renewal? Usually, what is the tenure of these renewals?</p> <p>(c) in your Qtr 1 2022 result, duopharma incurred an 8.858m impairment of inventories, please can you shed more light on this item? and why it had to be impaired? is this exercise done on the first qtr annually?</p>	<p>(b) Given Encik Leonard's impressive industry knowledge and performance, it would be in the enlightened interest of the Company to have the pleasure of Encik Leonard's leadership.</p> <p>How long is the remaining tenure of Encik Leonard? What is the usual tenure renewal for such positions?</p> <p>(c) In the result for Quarter 1 2022, Duopharma Biotech incurred an RM 8.858 million impairment in inventories. Kindly shed more light on this item and why it had to be impaired? Is this exercise done during the first quarter annually?</p>		<p>be fully depreciated once the K3 facility is ready.</p> <p>(b) The Board of Directors recognised the leadership of Encik Leonard in the Company. For information, Encik Leonard's current contract will run until 14 February 2023. That 6 months prior to the expiry of his contract, the NRC will deliberate on the tenure of any renewal of the Group Managing Director and will be recommended to the Board for approval.</p> <p>(c) The Group adopts a stock provision policy of providing for stocks 6 months before the expiry date and on specifically identified items that need to be provided for. This exercise is done quarterly basis and at the end of every quarter, the Company would review its entire inventory portfolio to decide what to impair/ reverse impairment or make provision for. The decision to be made would be discussed with the Company's external auditors</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
					as well to be aligned with the Company's policy.
54	TEOH HUI HAN	What is current DPHARMA market share in Malaysia?	What is the current market share of Duopharma Biotech in Malaysia?	Answer to Question 19 on page 38	The overall market share in Malaysia of Duopharma Biotech is 7.1% which includes imported medications and locally manufactured medication. In terms of volume, the overall market share of the Company would be much higher due to the generic sector.
55	PHUAN KEAN MING	Can u sharing some progress in ESG Duopharma?	What are some of the progresses made by Duopharma Biotech on the Environmental, Social and Governance ("ESG") front?	Answer to Question 20 on page 39	The Company had done a lot of work in relation to the ESG front and recognised some fundamental shifts that were occurring in the market. We started doing Sustainability Report much earlier compared to a lot of companies in Malaysia. After Duopharma Biotech's 5-year ESG strategy was presented and approved by the Board of Directors in Q1 2022, the Company made pledges to achieve carbon neutrality by 2030 and Net Zero GHG emission by 2050. Some of the initiatives are to achieve a sustainable supply chain, waste reduction, energy efficiency improvement, water

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
					stress/efficiency programs, diversity and inclusion in the workplace, and ISO 37001 Anti Bribery Management System certification for all sites in Duopharma Biotech Berhad. The Scope 1 and 2 Emission was completed, and now the Company had engaged a consultant to assist the Company with the Scope 3 Emission accounting. The GMD highlighted the Company started working towards Net Zero in 2022 to achieve the position in 2050, and the development would be shared with the shareholders annually.
56	SIAH KIM MENG	<p>(a) how many percent of the revenue of the company is contributed by the sale of specialty products?</p> <p>(b) What are the efforts to improve sales from oversea market?</p>	<p>(a) What percentage of the Company's revenue is contributed by the sale of specialty products?</p> <p>(b) What are Duopharma's efforts to improve sales from overseas markets?</p>		<p>(a) For FYE 2021, sales of our Ethical Specialty Products contributed approximately 20% to the Group's total revenue. One of the largest contributors was insulin sales to the Government.</p> <p>(b) Our model for moving into the international market is multi-fold which includes developing new dossiers/ products that are unique, ensuring manufacturing assets can support the export,</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
		(c) What are the new products that will be launched in this year?	(c) Kindly share the new products that Duopharma Biotech will be launching this year?		<p>and looking at what is manufactured in the markets domestically that is different. For example, the HAPI facility. The Company has launched Letrozole a product for breast cancer which product and already gaining interest from Pakistan and other regional countries as there are very few HAPI facilities available. We hope to increase our exports of unique products rather than commodity products. However, the matter would take some time due to the regulatory process for exports.</p> <p>(c) For Ethical, the Company will be launching products in a few therapeutic areas including Respiratory, Sensory, and Hypertension. In fact, there are products that have been developed but were unable to launch due to patent issues. We do design our product range to be able to be the first in the market once the patent expires. As for Consumer Healthcare, there are products under Champs Brand in</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
					Q3 2022 and another product in collaboration with SCM Lifescience, at a later point of the year.
57	TEOH HUI HAN LEE SZE TENG	Is the selling price adjustment being made in FY2022 to pass down the inflation on cost, increase in min wage and appreciation of USD on purchasing raw material?	Is the selling price adjustment being made in FY2022 to pass down the cost arising from inflation, increase in minimum wage and appreciation of USD on the purchases of raw materials?	Answer to Question 22 on page 40	Selling price adjustment is a continuous exercise taking into account impacts on our cost structure. We have adjusted our selling price in 2022 for some ranges of our products but it will be another review of price increases as the Company did not expect a high appreciation of USD against the MYR at the beginning of the year. The Company have to be cautious in recognising we are a generic manufacturer and the benefits of selling generic medications to the consumer are being priced competitively.
58	LEONG MEI YOKE	Why is the share price for Duopharma decreasing in value even though the demand for healthcare is increasing?	Kindly highlight why is the share price for Duopharma decreasing in value	Answer to Question 7 on page 34	Share price fluctuates according to various factors in the share market which are beyond our control.

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
			despite the increasing demand for healthcare products?		
59	TEH PENG TIN	How much does the company spend on this virtual agm ?	What is the total cost of Duopharma Biotech's virtual AGM?	Answer to Question 8 on page 34	This cost for virtual AGM would be approximately RM165,000.00 which is more cost-effective as compared to fully physical AGM.
60	HO YUEH WENG	Why are major shareholders also disposing our Co's shares so aggressively and causing a serious erosion of of our Co's share price? What is ailing our Co's future that key investors' interest are being reduced so significantly that minority shareholders are kept in the dark?	Why are the major shareholders aggressively disposing of the shares of Duopharma Biotech?	Answer to Question 9 on page 34	Shareholders' decision on shareholding is independent of management. To date, the major shareholder together with the unit trust funds managed by the major shareholder still maintains majority shareholding in the Company.
61	TEOH HUI HAN	(a) Does the increase in minimum wage significantly increase the labour contract workers? (b) Is the lack of foreign workers impacting company production?	(a) Does the increase in minimum wage significantly increase the number of contract workers? (b) Does the lack of foreign workers impact production?	Answers to Questions 10(a) and 10(b) on page 35	(a) The Company had adjusted its minimum wage in accordance with the Government policy and it does not lead to a significant increase in the ability to attract workers. (b) No, it does not impact production adversely. The Company tend to not use foreign workers within

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
					Duopharma. But those companies that did use foreign workers are now engaging local workers. We noticed that there are difficulties in recruiting local workers at the moment which the Company is addressing. The minimum wage increases our costs but has not improved the ability to attract workers.
62	CHOY YAU KEE	CHAIRMAN, you are still afraid to face the shareholders by holding the AGM in virtual meeting. Be BOLD by holding physical AGM and face the shareholders.	Will a physical AGM be held in the years moving forward?	Answer to Question 12 on page 35	<p>The Company has yet to decide on AGM forward moving forward. The MCO has forced the Company to hold a fully virtual AGM. With the growing numbers of foreign shareholders on the Company's shareholders list, it would preclude the foreign investors from being able to participate in the AGM.</p> <p>Moving forward, the chances are to hold the Company's AGM fully virtual physically or on a hybrid of which the decision on the meeting platform would be decided towards the end of the year.</p>

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
63	GOH SU LOOI @ GOH PEK LENG LEOW YUK LOONG	Post pandemic,the group's performance I believe will be much better.As such a better dividend rate shd be under consideration.thks. Will the company increase the dividend payout rate?	Would the Company consider a better dividend rate in light of the better performance in the post- pandemic environment?	Answer to Question 13 on page 36	The Board will decide on the dividend rate on multiple fronts by taking into consideration shareholders' needs, the company's de-gearing strategy as well as to conserve cash as working capital and fund existing business expansion.
64	GOH PEK HONG	Good morning to BoD, When will the company reward shareholders with bonus issue? Will shareholders be rewarded with doorgift for attending this agm remotely? Tq.	When will the Company reward shareholders with bonus issues?	Answer to Question 14 on page 36	The Company's most recent bonus issue was in 2021. Currently, we do not have any plan for new bonus issues but the Company review the matter on a regular basis and will proceed with bonus issue if suitable.
65	LOO YEW MING	Any succession planning to replace retiring directors so that they can reward the shareholders by giving increasing dividends, bonus issue, give extra shares, doorgift eg evoucher, ewallet etc, To assure that BOD take care of VALUED shareholders.	Does the Board have in place a succession plan for retiring Directors?	Answer to Question 15 on page 36	The Board has recently adopted a Succession Plan Policy for Non- Executive Directors. The succession plan is premised on a phased retirement plan and takes into account contingencies situations. The Company is formalising the succession plan and discussing it on a regular basis as an agenda item of the Nomination and Remuneration Committee ("NRC") meeting. The NRC not only discussing on the succession plan

No.	Shareholder/ Proxy	Raw Questions from Shareholder/ Proxy	Moderated Questions	Reference made of the Minutes of the 21 st Annual General Meeting	Answer(s)
					within Management but also discussing on the Board Succession Plan within the Board of Directors as well.
66	OOI CHENG KOOI LAU CHUAN HOOI SIAH KIM MENG	(a) As covid-19 pandemic has cool down, what is the company's future plan for this kind of medication? and is this kind of medication continue bring in extra revenue and net profit for the company?	(a) As the Covid-19 pandemic has tapered, what is the Company's future plan for Covid-19-related medication? Would this kind of medication continue to bring in extra revenue and net profit for the Company? (b) Pursuant to the bonus issue exercise in 2021, the bonus shares given to me were short of 1 unit due to the computation based on 2 different CDS accounts. Kindly clarify.	Answer to Questions 16(a) and 16(b) on pages 36 and 37	(a) We need to look at the available Covid-19 vaccine that we have. The Company also have a wide range of anti-infectives which sells well during the pandemic (b) The Share Registrar will contact and explain your entitlement after the meeting.